Page last updated: 2024-08-07 16:25:30
Adenosine receptor A2a
An adenosine receptor A2a that is encoded in the genome of rat. [OMA:P30543, PRO:DNx]
Synonyms
Research
Bioassay Publications (136)
| Timeframe | Studies on this Protein(%) | All Drugs % |
|---|
| pre-1990 | 17 (12.50) | 18.7374 |
| 1990's | 49 (36.03) | 18.2507 |
| 2000's | 37 (27.21) | 29.6817 |
| 2010's | 29 (21.32) | 24.3611 |
| 2020's | 4 (2.94) | 2.80 |
Compounds (213)
Drugs with Potency Measurements
| Drug | Taxonomy | Measurement | Average (mM) | Bioassay(s) | Publication(s) |
|---|
| ml106 | Rattus norvegicus (Norway rat) | Potency | 0.0708 | 1 | 0 |
| 6-(1,3-benzodioxol-5-yl)-N-(2-furanylmethyl)-N-methyl-4-quinazolinamine | Rattus norvegicus (Norway rat) | Potency | 0.0631 | 1 | 0 |
| N-(2-furanylmethyl)-6-(3-methoxyphenyl)-N-methyl-4-quinazolinamine | Rattus norvegicus (Norway rat) | Potency | 0.3548 | 1 | 0 |
| 6-(1,3-benzodioxol-5-yl)-N-[(3-methylphenyl)methyl]-4-quinazolinamine | Rattus norvegicus (Norway rat) | Potency | 0.1122 | 1 | 0 |
| 6-(2-chlorophenyl)-N-(3-pyridinylmethyl)-4-quinazolinamine | Rattus norvegicus (Norway rat) | Potency | 12.5893 | 1 | 0 |
| 6-(3-furanyl)-N-[(3-methylphenyl)methyl]-4-quinazolinamine | Rattus norvegicus (Norway rat) | Potency | 0.2512 | 1 | 0 |
| 6-(3-pyridinyl)-N-(3-pyridinylmethyl)-4-quinazolinamine | Rattus norvegicus (Norway rat) | Potency | 7.9433 | 1 | 0 |
| 6-(3-furanyl)-N-(thiophen-2-ylmethyl)-4-quinazolinamine | Rattus norvegicus (Norway rat) | Potency | 0.2239 | 1 | 0 |
| 6-(3-methoxyphenyl)-N-(3-pyridinylmethyl)-4-quinazolinamine | Rattus norvegicus (Norway rat) | Potency | 2.5119 | 1 | 0 |
| 6-(2-chlorophenyl)-N-(2-furanylmethyl)-N-methyl-4-quinazolinamine | Rattus norvegicus (Norway rat) | Potency | 10.0000 | 1 | 0 |
| 6-(3-methoxyphenyl)-N-(thiophen-2-ylmethyl)-4-quinazolinamine | Rattus norvegicus (Norway rat) | Potency | 1.0000 | 1 | 0 |
| 6-(3-furanyl)-N-(3-pyridinylmethyl)-4-quinazolinamine | Rattus norvegicus (Norway rat) | Potency | 0.5623 | 1 | 0 |
| N-[(3-methylphenyl)methyl]-6-(3-pyridinyl)-4-quinazolinamine | Rattus norvegicus (Norway rat) | Potency | 2.8184 | 1 | 0 |
| N-(2-furanylmethyl)-N-methyl-6-(1-methyl-5-indolyl)-4-quinazolinamine | Rattus norvegicus (Norway rat) | Potency | 14.1254 | 1 | 0 |
| 6-(2-chlorophenyl)-N-[(3-methylphenyl)methyl]-4-quinazolinamine | Rattus norvegicus (Norway rat) | Potency | 7.9433 | 1 | 0 |
| 6-(3-methoxyphenyl)-N-[(3-methylphenyl)methyl]-4-quinazolinamine | Rattus norvegicus (Norway rat) | Potency | 1.2589 | 1 | 0 |
| 6-(2,3-dihydro-1,4-benzodioxin-6-yl)-N-[(3-methylphenyl)methyl]-4-quinazolinamine | Rattus norvegicus (Norway rat) | Potency | 0.5623 | 1 | 0 |
| 6-(2-chlorophenyl)-N-(thiophen-2-ylmethyl)-4-quinazolinamine | Rattus norvegicus (Norway rat) | Potency | 6.3096 | 1 | 0 |
| 6-(3-chlorophenyl)-N-(thiophen-2-ylmethyl)-4-quinazolinamine | Rattus norvegicus (Norway rat) | Potency | 3.9811 | 1 | 0 |
| 6-(3-pyridinyl)-N-(thiophen-2-ylmethyl)-4-quinazolinamine | Rattus norvegicus (Norway rat) | Potency | 3.1623 | 1 | 0 |
| 6-(3-methylphenyl)-N-(thiophen-2-ylmethyl)-4-quinazolinamine | Rattus norvegicus (Norway rat) | Potency | 7.9433 | 1 | 0 |
| 6-(1-methyl-5-indolyl)-N-(thiophen-2-ylmethyl)-4-quinazolinamine | Rattus norvegicus (Norway rat) | Potency | 14.1254 | 1 | 0 |
| 6-(2,3-dihydro-1,4-benzodioxin-6-yl)-N-(thiophen-2-ylmethyl)-4-quinazolinamine | Rattus norvegicus (Norway rat) | Potency | 0.1413 | 1 | 0 |
| N-(1,3-benzodioxol-5-ylmethyl)-6-(2,3-dihydro-1,4-benzodioxin-6-yl)-4-quinazolinamine | Rattus norvegicus (Norway rat) | Potency | 1.7783 | 1 | 0 |
| 6-(2,3-dihydro-1,4-benzodioxin-6-yl)-N-(3-pyridinylmethyl)-4-quinazolinamine | Rattus norvegicus (Norway rat) | Potency | 0.3981 | 1 | 0 |
| 6-(1,3-benzodioxol-5-yl)-N-[(3-fluorophenyl)methyl]-4-quinazolinamine | Rattus norvegicus (Norway rat) | Potency | 0.1413 | 1 | 0 |
| 6-(3-chlorophenyl)-N-(3-pyridinylmethyl)-4-quinazolinamine | Rattus norvegicus (Norway rat) | Potency | 4.4668 | 1 | 0 |
| 6-(3-methylphenyl)-N-(3-pyridinylmethyl)-4-quinazolinamine | Rattus norvegicus (Norway rat) | Potency | 6.3096 | 1 | 0 |
| 6-(1,3-benzodioxol-5-yl)-N-(3-pyridinylmethyl)-4-quinazolinamine | Rattus norvegicus (Norway rat) | Potency | 0.1259 | 1 | 0 |
| N-(1,3-benzodioxol-5-ylmethyl)-6-(2-chlorophenyl)-4-quinazolinamine | Rattus norvegicus (Norway rat) | Potency | 14.1254 | 1 | 0 |
| N-(1,3-benzodioxol-5-ylmethyl)-6-(3-methoxyphenyl)-4-quinazolinamine | Rattus norvegicus (Norway rat) | Potency | 1.2589 | 1 | 0 |
| N-(1,3-benzodioxol-5-ylmethyl)-6-(3-pyridinyl)-4-quinazolinamine | Rattus norvegicus (Norway rat) | Potency | 7.0795 | 1 | 0 |
| N-(1,3-benzodioxol-5-ylmethyl)-6-(3-furanyl)-4-quinazolinamine | Rattus norvegicus (Norway rat) | Potency | 0.7079 | 1 | 0 |
| 6-(2-chlorophenyl)-N-[(4-methyl-2-thiophenyl)methyl]-4-quinazolinamine | Rattus norvegicus (Norway rat) | Potency | 8.9125 | 1 | 0 |
| 6-(3-chlorophenyl)-N-[(4-methyl-2-thiophenyl)methyl]-4-quinazolinamine | Rattus norvegicus (Norway rat) | Potency | 12.5893 | 1 | 0 |
| 6-(3-methoxyphenyl)-N-[(4-methyl-2-thiophenyl)methyl]-4-quinazolinamine | Rattus norvegicus (Norway rat) | Potency | 0.8913 | 1 | 0 |
| N-[(4-methyl-2-thiophenyl)methyl]-6-(3-pyridinyl)-4-quinazolinamine | Rattus norvegicus (Norway rat) | Potency | 4.4668 | 1 | 0 |
| 6-(1,3-benzodioxol-5-yl)-N-[(4-methyl-2-thiophenyl)methyl]-4-quinazolinamine | Rattus norvegicus (Norway rat) | Potency | 0.1585 | 1 | 0 |
| 6-(2,3-dihydro-1,4-benzodioxin-6-yl)-N-[(4-methyl-2-thiophenyl)methyl]-4-quinazolinamine | Rattus norvegicus (Norway rat) | Potency | 0.4467 | 1 | 0 |
| 6-(3-furanyl)-N-[(4-methyl-2-thiophenyl)methyl]-4-quinazolinamine | Rattus norvegicus (Norway rat) | Potency | 0.5623 | 1 | 0 |
Drugs with Inhibition Measurements
| Drug | Taxonomy | Measurement | Average (mM) | Bioassay(s) | Publication(s) |
|---|
| 9-ethyladenine | Rattus norvegicus (Norway rat) | Ki | 5.6000 | 1 | 1 |
| 4-hydroxybenzoic acid | Rattus norvegicus (Norway rat) | Ki | 5.1200 | 2 | 2 |
| catechol | Rattus norvegicus (Norway rat) | Ki | 381.4500 | 2 | 2 |
| gallic acid | Rattus norvegicus (Norway rat) | Ki | 6.5500 | 2 | 2 |
| phenol | Rattus norvegicus (Norway rat) | Ki | 360.7500 | 2 | 2 |
| xanthine | Rattus norvegicus (Norway rat) | Ki | 130.0000 | 1 | 1 |
| 1,3-diethyl-8-phenylxanthine | Rattus norvegicus (Norway rat) | Ki | 0.8360 | 1 | 1 |
| 1,3-dipropyl-8-cyclopentylxanthine | Rattus norvegicus (Norway rat) | Ki | 0.3468 | 18 | 24 |
| 1,3-dipropyl-8-(4-sulfophenyl)xanthine | Rattus norvegicus (Norway rat) | Ki | 4.0129 | 5 | 7 |
| enprofylline | Rattus norvegicus (Norway rat) | Ki | 109.1667 | 4 | 6 |
| methylbufotenin | Rattus norvegicus (Norway rat) | IC50 | 0.0150 | 1 | 1 |
| 7-(2-chloroethyl)theophylline | Rattus norvegicus (Norway rat) | Ki | 4.2300 | 1 | 2 |
| 8-(4-sulfophenyl)theophylline | Rattus norvegicus (Norway rat) | Ki | 5.3600 | 3 | 5 |
| 8-cyclopentyl-1,3-dimethylxanthine | Rattus norvegicus (Norway rat) | Ki | 0.5733 | 2 | 3 |
| 8-phenyltheophylline | Rattus norvegicus (Norway rat) | Ki | 1.2198 | 6 | 9 |
| acetazolamide | Rattus norvegicus (Norway rat) | Ki | 0.0185 | 3 | 3 |
| theophylline | Rattus norvegicus (Norway rat) | Ki | 15.9652 | 24 | 31 |
| aspirin | Rattus norvegicus (Norway rat) | IC50 | 5,000.0000 | 1 | 1 |
| benextramine | Rattus norvegicus (Norway rat) | IC50 | 4.0200 | 1 | 1 |
| caffeine | Rattus norvegicus (Norway rat) | IC50 | 63.0000 | 1 | 5 |
| caffeine | Rattus norvegicus (Norway rat) | Ki | 160.9033 | 25 | 30 |
| cgs 15943 | Rattus norvegicus (Norway rat) | IC50 | 0.0029 | 2 | 6 |
| cgs 15943 | Rattus norvegicus (Norway rat) | Ki | 0.4732 | 6 | 7 |
| ebastine | Rattus norvegicus (Norway rat) | IC50 | 0.0470 | 1 | 1 |
| ibuprofen | Rattus norvegicus (Norway rat) | IC50 | 1,030.0000 | 1 | 1 |
| indomethacin | Rattus norvegicus (Norway rat) | IC50 | 164.0000 | 1 | 1 |
| 1-methyl-3-isobutylxanthine | Rattus norvegicus (Norway rat) | IC50 | 13.0000 | 1 | 5 |
| 1-methyl-3-isobutylxanthine | Rattus norvegicus (Norway rat) | Ki | 6.1150 | 7 | 10 |
| losartan | Rattus norvegicus (Norway rat) | IC50 | 0.0032 | 1 | 1 |
| n 0840 | Rattus norvegicus (Norway rat) | Ki | 18.0000 | 2 | 2 |
| nicardipine | Rattus norvegicus (Norway rat) | Ki | 63.8000 | 1 | 1 |
| nifedipine | Rattus norvegicus (Norway rat) | Ki | 14.1000 | 1 | 2 |
| nimodipine | Rattus norvegicus (Norway rat) | Ki | 44.3000 | 1 | 1 |
| nitrendipine | Rattus norvegicus (Norway rat) | Ki | 23.0000 | 1 | 1 |
| n-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide | Rattus norvegicus (Norway rat) | IC50 | 53.0000 | 1 | 1 |
| rolipram | Rattus norvegicus (Norway rat) | IC50 | 100.0000 | 1 | 5 |
| sq 22536 | Rattus norvegicus (Norway rat) | Ki | 2.4000 | 1 | 1 |
| tetrahydropapaverine | Rattus norvegicus (Norway rat) | Ki | 10.0000 | 1 | 1 |
| theobromine | Rattus norvegicus (Norway rat) | Ki | 250.0000 | 2 | 3 |
| 8-(4-((2-aminoethyl)aminocarbonylmethyloxy)phenyl)-1,3-dipropylxanthine | Rattus norvegicus (Norway rat) | Ki | 0.0510 | 6 | 7 |
| 2-chloroadenosine | Rattus norvegicus (Norway rat) | IC50 | 0.1600 | 1 | 2 |
| 2-chloroadenosine | Rattus norvegicus (Norway rat) | Ki | 0.1584 | 7 | 8 |
| catechin | Rattus norvegicus (Norway rat) | IC50 | 5,910.0000 | 1 | 1 |
| cyproterone acetate | Rattus norvegicus (Norway rat) | Ki | 0.3360 | 1 | 3 |
| syringic acid | Rattus norvegicus (Norway rat) | Ki | 8.4750 | 2 | 2 |
| toyocamycin | Rattus norvegicus (Norway rat) | IC50 | 3,235,940.0000 | 1 | 1 |
| nsc 65346 | Rattus norvegicus (Norway rat) | IC50 | 2,137,960.0000 | 1 | 1 |
| tetrahydropapaveroline | Rattus norvegicus (Norway rat) | Ki | 40.0000 | 1 | 1 |
| quinpirole | Rattus norvegicus (Norway rat) | Ki | 3.0000 | 1 | 1 |
| niguldipine | Rattus norvegicus (Norway rat) | Ki | 55.0000 | 2 | 2 |
| adenosine | Rattus norvegicus (Norway rat) | Ki | 0.0240 | 3 | 3 |
| xanthobine | Rattus norvegicus (Norway rat) | Ki | 12.0000 | 1 | 1 |
| rolofylline | Rattus norvegicus (Norway rat) | Ki | 0.3600 | 4 | 4 |
| isoguanosine | Rattus norvegicus (Norway rat) | Ki | 0.3300 | 1 | 1 |
| 3'-amino-3'-deoxyadenosine | Rattus norvegicus (Norway rat) | Ki | 0.0100 | 1 | 2 |
| aristeromycin | Rattus norvegicus (Norway rat) | Ki | 2.1500 | 1 | 1 |
| 9-methyladenine | Rattus norvegicus (Norway rat) | Ki | 16.3000 | 2 | 2 |
| 3-methylxanthine | Rattus norvegicus (Norway rat) | Ki | 240.0000 | 1 | 2 |
| 1-methylxanthine | Rattus norvegicus (Norway rat) | Ki | 20.8800 | 3 | 5 |
| catalpol | Rattus norvegicus (Norway rat) | IC50 | 47.8000 | 1 | 1 |
| n(6)-benzyladenosine | Rattus norvegicus (Norway rat) | Ki | 0.5065 | 2 | 2 |
| 1,3-dipropyl-8-(2-amino-4-chlorophenyl)xanthine | Rattus norvegicus (Norway rat) | Ki | 1.0000 | 1 | 1 |
| phenylisopropyladenosine | Rattus norvegicus (Norway rat) | IC50 | 0.2898 | 2 | 4 |
| phenylisopropyladenosine | Rattus norvegicus (Norway rat) | Ki | 2.4882 | 12 | 13 |
| bromotubercidin | Rattus norvegicus (Norway rat) | IC50 | 8,317,640.0000 | 1 | 1 |
| 5-iodotubercidin | Rattus norvegicus (Norway rat) | IC50 | 38,904,500.0000 | 1 | 1 |
| 5-chlorotubercidin | Rattus norvegicus (Norway rat) | IC50 | 4,786,300.0000 | 1 | 1 |
| 5'-n-methylcarboxamideadenosine | Rattus norvegicus (Norway rat) | Ki | 0.0669 | 2 | 3 |
| 3,7-dimethyl-1-propargylxanthine | Rattus norvegicus (Norway rat) | Ki | 7.8000 | 2 | 2 |
| n(6)-phenyladenosine | Rattus norvegicus (Norway rat) | IC50 | 0.6600 | 1 | 1 |
| n(6)-phenyladenosine | Rattus norvegicus (Norway rat) | Ki | 25.6000 | 2 | 2 |
| bw a1433u | Rattus norvegicus (Norway rat) | Ki | 0.3468 | 3 | 4 |
| n-(2-(dimethylamino)ethyl)-n-methyl-4-(2,3,6,7-tetrahydro-2,6-dioxo-1,3-dipropyl-1h-purin-8-yl)benzenesulfonamide | Rattus norvegicus (Norway rat) | Ki | 0.0225 | 2 | 3 |
| n(6)-(3-iodobenzyl)-5'-n-methylcarboxamidoadenosine | Rattus norvegicus (Norway rat) | Ki | 0.0560 | 7 | 8 |
| 2-chloro-n(6)cyclopentyladenosine | Rattus norvegicus (Norway rat) | Ki | 0.7408 | 6 | 6 |
| cp 66713 | Rattus norvegicus (Norway rat) | IC50 | 0.0210 | 1 | 5 |
| cp 66713 | Rattus norvegicus (Norway rat) | Ki | 0.0210 | 1 | 1 |
| 8-(4-carboxymethyloxy)phenyl-1,3-dipropylxanthine | Rattus norvegicus (Norway rat) | Ki | 2.2129 | 3 | 3 |
| 1-propylxanthine | Rattus norvegicus (Norway rat) | Ki | 33.0000 | 1 | 2 |
| 1,3-dipropyl-8-phenylxanthine | Rattus norvegicus (Norway rat) | Ki | 0.9917 | 7 | 12 |
| 8-(dicyclopropylmethyl)-1,3-dipropylxanthine | Rattus norvegicus (Norway rat) | Ki | 0.4300 | 3 | 3 |
| kfm 19 | Rattus norvegicus (Norway rat) | Ki | 2.7000 | 1 | 1 |
| 8-cyclopentyl-3-(3-((4-(fluorosulfonyl)benzoyl)oxy)propyl)-1-propylxanthine | Rattus norvegicus (Norway rat) | IC50 | 4.5006 | 2 | 2 |
| 2-(1-octynyl)adenosine | Rattus norvegicus (Norway rat) | Ki | 0.0067 | 3 | 6 |
| 1-isoamyl-3-isobutylxanthine | Rattus norvegicus (Norway rat) | Ki | 6.5000 | 1 | 2 |
| naproxen | Rattus norvegicus (Norway rat) | IC50 | 1,015.0000 | 1 | 1 |
| 1-deazaadenosine | Rattus norvegicus (Norway rat) | Ki | 2.9000 | 1 | 1 |
| 1,3-dipropyl-7-methylxanthine | Rattus norvegicus (Norway rat) | Ki | 6.0333 | 3 | 6 |
| bw a522 | Rattus norvegicus (Norway rat) | Ki | 0.7000 | 1 | 1 |
| 2-hexynyladenosine-5'-n-ethylcarboxamide | Rattus norvegicus (Norway rat) | Ki | 0.0038 | 4 | 6 |
| 1,3-dipropylxanthine | Rattus norvegicus (Norway rat) | Ki | 4.5846 | 9 | 13 |
| zm 241385 | Rattus norvegicus (Norway rat) | Ki | 0.1073 | 5 | 5 |
| sch 58261 | Rattus norvegicus (Norway rat) | Ki | 0.2324 | 9 | 9 |
| 5-chloropyrazinamide | Rattus norvegicus (Norway rat) | IC50 | 33.2000 | 1 | 1 |
| regadenoson | Rattus norvegicus (Norway rat) | Ki | 0.2900 | 1 | 4 |
| 8-cyclohexylcaffeine | Rattus norvegicus (Norway rat) | Ki | 2.1450 | 2 | 4 |
| mrs 1067 | Rattus norvegicus (Norway rat) | IC50 | 0.1000 | 1 | 1 |
| mrs 1067 | Rattus norvegicus (Norway rat) | Ki | 55.0000 | 2 | 2 |
| diethyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate | Rattus norvegicus (Norway rat) | Ki | 18.2000 | 1 | 1 |
| mrs 1191 | Rattus norvegicus (Norway rat) | Ki | 0.1000 | 1 | 2 |
| mrs 1220 | Rattus norvegicus (Norway rat) | Ki | 0.0341 | 5 | 7 |
| 5'-methylthioadenosine | Rattus norvegicus (Norway rat) | Ki | 1.1633 | 2 | 3 |
| (R)-norlaudanosoline | Rattus norvegicus (Norway rat) | Ki | 25.0000 | 1 | 1 |
| ferulic acid | Rattus norvegicus (Norway rat) | Ki | 8.4200 | 2 | 2 |
| 2'-amino-2'-deoxyadenosine | Rattus norvegicus (Norway rat) | Ki | 0.0100 | 1 | 2 |
| adenosine-5'-(n-ethylcarboxamide) | Rattus norvegicus (Norway rat) | IC50 | 0.0513 | 5 | 10 |
| adenosine-5'-(n-ethylcarboxamide) | Rattus norvegicus (Norway rat) | Ki | 0.0116 | 14 | 18 |
| 1-deaza-2-chloro-n(6)-cyclopentyladenosine | Rattus norvegicus (Norway rat) | Ki | 8.0200 | 2 | 2 |
| trans-4-coumaric acid | Rattus norvegicus (Norway rat) | Ki | 5.9550 | 2 | 2 |
| 1,4-diphenylbutadiene | Rattus norvegicus (Norway rat) | Ki | 0.0006 | 1 | 1 |
| n(6)-cyclopentyladenosine | Rattus norvegicus (Norway rat) | IC50 | 1.1600 | 1 | 2 |
| n(6)-cyclopentyladenosine | Rattus norvegicus (Norway rat) | Ki | 0.8832 | 14 | 15 |
| caffeic acid | Rattus norvegicus (Norway rat) | Ki | 7.5650 | 2 | 2 |
| N-[4-(2-pyridinyl)-2-thiazolyl]cyclopentanecarboxamide | Rattus norvegicus (Norway rat) | Ki | 1.3000 | 1 | 1 |
| 3-(methylthio)-4-oxo-6,7-dihydro-5H-2-benzothiophene-1-carboxylic acid ethyl ester | Rattus norvegicus (Norway rat) | Ki | 3.6600 | 1 | 1 |
| fk 838 | Rattus norvegicus (Norway rat) | Ki | 1.2020 | 1 | 1 |
| 2-chloro-n(6)-(3-iodobenzyl)adenosine-5'-n-methyluronamide | Rattus norvegicus (Norway rat) | Ki | 0.4700 | 5 | 5 |
| adenosine-5'-(N-propyl)carboxamide | Rattus norvegicus (Norway rat) | Ki | 0.5500 | 1 | 1 |
| 2-((2-aminoethylamino)carbonylethylphenylethylamino)-5'-n-ethylcarboxamidoadenosine | Rattus norvegicus (Norway rat) | Ki | 0.0057 | 3 | 4 |
| 2-(4-(2-carboxyethyl)phenethylamino)-5'-n-ethylcarboxamidoadenosine | Rattus norvegicus (Norway rat) | Ki | 0.0381 | 8 | 11 |
| mrs 1523 | Rattus norvegicus (Norway rat) | Ki | 2.0625 | 2 | 4 |
| cyclo(d-tyrosyl-arginyl-arginyl-3-(2-naphthyl)alanyl-glycyl) | Rattus norvegicus (Norway rat) | IC50 | 0.1260 | 1 | 1 |
| quercetin | Rattus norvegicus (Norway rat) | Ki | 5.1250 | 2 | 2 |
| quercitrin | Rattus norvegicus (Norway rat) | IC50 | 2,000.0000 | 1 | 1 |
| genistein | Rattus norvegicus (Norway rat) | Ki | 36.0000 | 1 | 1 |
| hispidol | Rattus norvegicus (Norway rat) | Ki | 100.0000 | 1 | 1 |
| ellagic acid | Rattus norvegicus (Norway rat) | Ki | 7.6150 | 2 | 2 |
| mre 3008-f20 | Rattus norvegicus (Norway rat) | Ki | 1.9930 | 1 | 1 |
| istradefylline | Rattus norvegicus (Norway rat) | IC50 | 0.2280 | 1 | 1 |
| istradefylline | Rattus norvegicus (Norway rat) | Ki | 2.1704 | 5 | 5 |
| psb 1115 | Rattus norvegicus (Norway rat) | Ki | 17.9000 | 2 | 2 |
| n-(1-methyl-2-phenylethyl)adenosine, (s)-isomer | Rattus norvegicus (Norway rat) | Ki | 13.4638 | 7 | 8 |
| 8-(3-chlorostyryl)caffeine | Rattus norvegicus (Norway rat) | Ki | 0.2793 | 4 | 4 |
| bw a1433 | Rattus norvegicus (Norway rat) | Ki | 0.8000 | 2 | 2 |
| fk 453 | Rattus norvegicus (Norway rat) | IC50 | 11.3000 | 1 | 1 |
| kf 17837 | Rattus norvegicus (Norway rat) | Ki | 0.0181 | 5 | 6 |
| bay-k-8644, (-)-isomer | Rattus norvegicus (Norway rat) | Ki | 86.3000 | 2 | 2 |
| mrs 1754 | Rattus norvegicus (Norway rat) | Ki | 0.6120 | 3 | 4 |
| bay-k-8644 | Rattus norvegicus (Norway rat) | Ki | 35.1000 | 2 | 2 |
| cv 1808 | Rattus norvegicus (Norway rat) | IC50 | 0.1450 | 1 | 2 |
| cv 1808 | Rattus norvegicus (Norway rat) | Ki | 0.0968 | 4 | 6 |
| dexniguldipine | Rattus norvegicus (Norway rat) | Ki | 100.0000 | 1 | 1 |
| 5'-amino-5'-deoxyadenosine | Rattus norvegicus (Norway rat) | Ki | 0.0100 | 1 | 2 |
| n(6)-cyclohexyladenosine | Rattus norvegicus (Norway rat) | IC50 | 0.5880 | 4 | 9 |
| n(6)-cyclohexyladenosine | Rattus norvegicus (Norway rat) | Ki | 5.3238 | 5 | 6 |
| mrs 1097 | Rattus norvegicus (Norway rat) | Ki | 4.7700 | 4 | 4 |
| 3-iodo-4-aminobenzyl-5'-N-methylcarboxamidoadenosine | Rattus norvegicus (Norway rat) | Ki | 0.1970 | 3 | 4 |
| 2-(2-furanyl)-7-(2-(4-(4-(2-methoxyethoxy)phenyl)-1-piperazinyl)ethyl)-7h-pyrazolo(4,3-e)(1,2,4)triazolo(1,5-c)pyrimidine-5-amine | Rattus norvegicus (Norway rat) | Ki | 0.5012 | 2 | 2 |
| vuf 8504 | Rattus norvegicus (Norway rat) | Ki | 10.0000 | 2 | 2 |
| n(6)-(2,2-diphenylethyl)adenosine | Rattus norvegicus (Norway rat) | Ki | 0.0417 | 3 | 3 |
| cgs 24012 | Rattus norvegicus (Norway rat) | Ki | 0.0051 | 4 | 9 |
| n-cyclopropyl adenosine-5'-carboxamide | Rattus norvegicus (Norway rat) | Ki | 0.0115 | 4 | 5 |
| abt-737 | Rattus norvegicus (Norway rat) | IC50 | 0.0200 | 1 | 1 |
| tozadenant | Rattus norvegicus (Norway rat) | Ki | 0.0187 | 1 | 1 |
| psb 36 | Rattus norvegicus (Norway rat) | Ki | 0.5520 | 1 | 1 |
| lj 529 | Rattus norvegicus (Norway rat) | Ki | 0.3480 | 1 | 1 |
| psb603 | Rattus norvegicus (Norway rat) | Ki | 10.0000 | 1 | 1 |
| psb 11 | Rattus norvegicus (Norway rat) | Ki | 2.1000 | 2 | 2 |
| cgs 15696 | Rattus norvegicus (Norway rat) | Ki | 4.3800 | 1 | 1 |
Drugs with Activation Measurements
Drugs with Other Measurements
| Drug | Taxonomy | Measurement | Average (mM) | Bioassay(s) | Publication(s) |
|---|
| histamine | Rattus norvegicus (Norway rat) | KA | 125.0000 | 1 | 2 |
| 1,3-dipropyl-8-cyclopentylxanthine | Rattus norvegicus (Norway rat) | Kb | 0.2500 | 1 | 1 |
| 1,3-dipropyl-8-cyclopentylxanthine | Rattus norvegicus (Norway rat) | Ratio | 0.3400 | 1 | 2 |
| enprofylline | Rattus norvegicus (Norway rat) | Kb | 120.0000 | 1 | 1 |
| 8-(4-sulfophenyl)theophylline | Rattus norvegicus (Norway rat) | Ratio | 1.5000 | 1 | 2 |
| 8-cyclopentyl-1,3-dimethylxanthine | Rattus norvegicus (Norway rat) | Ratio | 1.4000 | 1 | 2 |
| 8-phenyltheophylline | Rattus norvegicus (Norway rat) | Ratio | 0.8500 | 1 | 2 |
| theophylline | Rattus norvegicus (Norway rat) | Kb | 13.7000 | 1 | 1 |
| theophylline | Rattus norvegicus (Norway rat) | Ratio | 25.0000 | 1 | 2 |
| caffeine | Rattus norvegicus (Norway rat) | Kb | 36.0000 | 1 | 1 |
| caffeine | Rattus norvegicus (Norway rat) | Ratio | 48.0000 | 1 | 2 |
| cgs 15943 | Rattus norvegicus (Norway rat) | Ratio | 0.0033 | 1 | 2 |
| 8-(4-((2-aminoethyl)aminocarbonylmethyloxy)phenyl)-1,3-dipropylxanthine | Rattus norvegicus (Norway rat) | Ratio | 0.0600 | 1 | 2 |
| levodopa | Rattus norvegicus (Norway rat) | KA | 11.4000 | 1 | 2 |
| tyrosine | Rattus norvegicus (Norway rat) | KA | 0.0110 | 1 | 2 |
| phenylalanine | Rattus norvegicus (Norway rat) | KA | 0.0130 | 1 | 2 |
| histidine | Rattus norvegicus (Norway rat) | KA | 10.9000 | 1 | 2 |
| aminoethylpiperazine | Rattus norvegicus (Norway rat) | KA | 2.3000 | 1 | 2 |
| 2-chloroadenosine | Rattus norvegicus (Norway rat) | EC25 | 0.0130 | 1 | 1 |
| 2-chloroadenosine | Rattus norvegicus (Norway rat) | Ratio | 0.0630 | 1 | 2 |
| 2-(aminomethyl)pyridine | Rattus norvegicus (Norway rat) | KA | 34.0000 | 1 | 2 |
| rolofylline | Rattus norvegicus (Norway rat) | Ratio | 0.3800 | 1 | 2 |
| copper histidine | Rattus norvegicus (Norway rat) | KA | 43.0000 | 1 | 2 |
| D-tyrosine | Rattus norvegicus (Norway rat) | KA | 0.0870 | 1 | 2 |
| phenylalanine | Rattus norvegicus (Norway rat) | KA | 0.0350 | 1 | 2 |
| 2-(2-aminoethyl)pyridine | Rattus norvegicus (Norway rat) | KA | 15.0000 | 1 | 2 |
| n(6)-benzyladenosine | Rattus norvegicus (Norway rat) | EC25 | 0.0350 | 1 | 1 |
| D-dopa | Rattus norvegicus (Norway rat) | KA | 7.8000 | 1 | 2 |
| 1,3-dipropyl-8-(2-amino-4-chlorophenyl)xanthine | Rattus norvegicus (Norway rat) | Ratio | 0.0920 | 1 | 2 |
| phenylisopropyladenosine | Rattus norvegicus (Norway rat) | EC25 | 0.0100 | 1 | 1 |
| phenylisopropyladenosine | Rattus norvegicus (Norway rat) | Ratio | 0.1240 | 1 | 2 |
| 3,7-dimethyl-1-propargylxanthine | Rattus norvegicus (Norway rat) | Ratio | 9.6000 | 1 | 2 |
| n(6)-phenyladenosine | Rattus norvegicus (Norway rat) | Ratio | 0.6630 | 1 | 4 |
| bw a1433u | Rattus norvegicus (Norway rat) | Kb | 0.6400 | 1 | 1 |
| 2-chloro-n(6)cyclopentyladenosine | Rattus norvegicus (Norway rat) | Ratio | 0.9500 | 1 | 2 |
| cp 66713 | Rattus norvegicus (Norway rat) | Ratio | 0.0210 | 1 | 2 |
| adenosine amine congener | Rattus norvegicus (Norway rat) | Ratio | 0.2100 | 1 | 2 |
| 8-(4-carboxymethyloxy)phenyl-1,3-dipropylxanthine | Rattus norvegicus (Norway rat) | Ratio | 2.2000 | 1 | 2 |
| 1,3-dipropyl-8-phenylxanthine | Rattus norvegicus (Norway rat) | Kb | 2.3000 | 1 | 1 |
| 8-(dicyclopropylmethyl)-1,3-dipropylxanthine | Rattus norvegicus (Norway rat) | Ratio | 0.4300 | 1 | 2 |
| kfm 19 | Rattus norvegicus (Norway rat) | Ratio | 1.5100 | 1 | 2 |
| 2-(1-octynyl)adenosine | Rattus norvegicus (Norway rat) | Ratio | 0.0120 | 1 | 2 |
| 4-aminophenylalanine | Rattus norvegicus (Norway rat) | KA | 0.1500 | 1 | 2 |
| 1,3-dipropylxanthine | Rattus norvegicus (Norway rat) | Kb | 5.4000 | 1 | 1 |
| zm 241385 | Rattus norvegicus (Norway rat) | INH | 0.0003 | 1 | 1 |
| 4-2-Aminoethyl-morpholine | Rattus norvegicus (Norway rat) | KA | 0.1900 | 1 | 2 |
| adenosine-5'-(n-ethylcarboxamide) | Rattus norvegicus (Norway rat) | Ratio | 0.0103 | 1 | 2 |
| n(6)-cyclopentyladenosine | Rattus norvegicus (Norway rat) | EC25 | 0.1000 | 1 | 1 |
| n(6)-cyclopentyladenosine | Rattus norvegicus (Norway rat) | Ratio | 0.4620 | 1 | 2 |
| 2-(4-(2-carboxyethyl)phenethylamino)-5'-n-ethylcarboxamidoadenosine | Rattus norvegicus (Norway rat) | Ratio | 0.0150 | 1 | 2 |
| cv 1808 | Rattus norvegicus (Norway rat) | EC25 | 0.0030 | 1 | 1 |
| cv 1808 | Rattus norvegicus (Norway rat) | Ratio | 0.1190 | 1 | 2 |
| n(6)-cyclohexyladenosine | Rattus norvegicus (Norway rat) | Ratio | 0.5140 | 1 | 2 |
| 2-(2-furanyl)-7-(2-(4-(4-(2-methoxyethoxy)phenyl)-1-piperazinyl)ethyl)-7h-pyrazolo(4,3-e)(1,2,4)triazolo(1,5-c)pyrimidine-5-amine | Rattus norvegicus (Norway rat) | Kb | 0.0007 | 1 | 1 |
| n(6)-(2,2-diphenylethyl)adenosine | Rattus norvegicus (Norway rat) | EC25 | 0.0100 | 1 | 1 |
| n(6)-(2,2-diphenylethyl)adenosine | Rattus norvegicus (Norway rat) | Ratio | 0.0250 | 1 | 2 |
| cgs 24012 | Rattus norvegicus (Norway rat) | Ratio | 0.0044 | 1 | 2 |
| psb 11 | Rattus norvegicus (Norway rat) | Kb | 2.5000 | 1 | 1 |
1,3,7-Triethyl-substituted xanthines--possess nanomolar affinity for the adenosine A1 receptor.Bioorganic & medicinal chemistry, , Oct-15, Volume: 23, Issue:20, 2015
2-Amino-N-pyrimidin-4-ylacetamides as A2A receptor antagonists: 2. Reduction of hERG activity, observed species selectivity, and structure-activity relationships.Journal of medicinal chemistry, , Mar-27, Volume: 51, Issue:6, 2008
Synthesis and adenosine receptor binding studies of some novel triazolothienopyrimidines.European journal of medicinal chemistry, , Volume: 43, Issue:3, 2008
Development of spin-labeled probes for adenosine receptors.Journal of medicinal chemistry, , Mar-24, Volume: 48, Issue:6, 2005
Structure-activity relationships at human and rat A2B adenosine receptors of xanthine derivatives substituted at the 1-, 3-, 7-, and 8-positions.Journal of medicinal chemistry, , May-23, Volume: 45, Issue:11, 2002
1,8-disubstituted xanthine derivatives: synthesis of potent A2B-selective adenosine receptor antagonists.Journal of medicinal chemistry, , Mar-28, Volume: 45, Issue:7, 2002
Synthesis and biological evaluation of the enantiomers of the potent and selective A1-adenosine antagonist 1,3-dipropyl-8-[2-(5,6-epoxynorbonyl)]-xanthine.Journal of medicinal chemistry, , Jun-06, Volume: 40, Issue:12, 1997
Pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine derivatives: potent and selective A(2A) adenosine antagonists.Journal of medicinal chemistry, , Mar-01, Volume: 39, Issue:5, 1996
Structure-activity relationships of 1,3-dialkylxanthine derivatives at rat A3 adenosine receptors.Journal of medicinal chemistry, , Sep-30, Volume: 37, Issue:20, 1994
Adenosine A1 antagonists. 3. Structure-activity relationships on amelioration against scopolamine- or N6-((R)-phenylisopropyl)adenosine-induced cognitive disturbance.Journal of medicinal chemistry, , Aug-20, Volume: 36, Issue:17, 1993
8-Polycycloalkyl-1,3-dipropylxanthines as potent and selective antagonists for A1-adenosine receptors.Journal of medicinal chemistry, , Mar-06, Volume: 35, Issue:5, 1992
(E)-1,3-dialkyl-7-methyl-8-(3,4,5-trimethoxystyryl)xanthines: potent and selective adenosine A2 antagonists.Journal of medicinal chemistry, , Jun-12, Volume: 35, Issue:12, 1992
Adenosine receptors: pharmacology, structure-activity relationships, and therapeutic potential.Journal of medicinal chemistry, , Feb-07, Volume: 35, Issue:3, 1992
8-(Dicyclopropylmethyl)-1,3-dipropylxanthine: a potent and selective adenosine A1 antagonist with renal protective and diuretic activities.Journal of medicinal chemistry, , Volume: 34, Issue:1, 1991
Structure-activity relationships of 8-cycloalkyl-1,3-dipropylxanthines as antagonists of adenosine receptors.Journal of medicinal chemistry, , Volume: 33, Issue:7, 1990
Sulfur-containing 1,3-dialkylxanthine derivatives as selective antagonists at A1-adenosine receptors.Journal of medicinal chemistry, , Volume: 32, Issue:8, 1989
Effects of 8-phenyl and 8-cycloalkyl substituents on the activity of mono-, di-, and trisubstituted alkylxanthines with substitution at the 1-, 3-, and 7-positions.Journal of medicinal chemistry, , Volume: 32, Issue:6, 1989
8-Aryl-and 8-cycloalkyl-1,3-dipropylxanthines: further potent and selective antagonists for A1-adenosine receptors.Journal of medicinal chemistry, , Volume: 31, Issue:3, 1988
Structure-activity relationships of 1,3-dialkylxanthine derivatives at rat A3 adenosine receptors.Journal of medicinal chemistry, , Sep-30, Volume: 37, Issue:20, 1994
Effect of trifluoromethyl and other substituents on activity of xanthines at adenosine receptors.Journal of medicinal chemistry, , Sep-03, Volume: 36, Issue:18, 1993
Effects of 8-phenyl and 8-cycloalkyl substituents on the activity of mono-, di-, and trisubstituted alkylxanthines with substitution at the 1-, 3-, and 7-positions.Journal of medicinal chemistry, , Volume: 32, Issue:6, 1989
Analogues of 1,3-dipropyl-8-phenylxanthine: enhancement of selectivity at A1-adenosine receptors by aryl substituents.Journal of medicinal chemistry, , Volume: 29, Issue:8, 1986
1-alkyl-8-(piperazine-1-sulfonyl)phenylxanthines: development and characterization of adenosine A2B receptor antagonists and a new radioligand with subnanomolar affinity and subtype specificity.Journal of medicinal chemistry, , Jul-09, Volume: 52, Issue:13, 2009
Imidazo[2,1-i]purin-5-ones and related tricyclic water-soluble purine derivatives: potent A(2A)- and A(3)-adenosine receptor antagonists.Journal of medicinal chemistry, , Aug-01, Volume: 45, Issue:16, 2002
Imidazodiazepinediones: a new class of adenosine receptor antagonists.Journal of medicinal chemistry, , Volume: 33, Issue:10, 1990
Effects of 8-phenyl and 8-cycloalkyl substituents on the activity of mono-, di-, and trisubstituted alkylxanthines with substitution at the 1-, 3-, and 7-positions.Journal of medicinal chemistry, , Volume: 32, Issue:6, 1989
Effect of trifluoromethyl and other substituents on activity of xanthines at adenosine receptors.Journal of medicinal chemistry, , Sep-03, Volume: 36, Issue:18, 1993
Adenosine receptors: pharmacology, structure-activity relationships, and therapeutic potential.Journal of medicinal chemistry, , Feb-07, Volume: 35, Issue:3, 1992
Effects of 8-phenyl and 8-cycloalkyl substituents on the activity of mono-, di-, and trisubstituted alkylxanthines with substitution at the 1-, 3-, and 7-positions.Journal of medicinal chemistry, , Volume: 32, Issue:6, 1989
Adenosine receptors: pharmacology, structure-activity relationships, and therapeutic potential.Journal of medicinal chemistry, , Feb-07, Volume: 35, Issue:3, 1992
Sulfur-containing 1,3-dialkylxanthine derivatives as selective antagonists at A1-adenosine receptors.Journal of medicinal chemistry, , Volume: 32, Issue:8, 1989
Effects of 8-phenyl and 8-cycloalkyl substituents on the activity of mono-, di-, and trisubstituted alkylxanthines with substitution at the 1-, 3-, and 7-positions.Journal of medicinal chemistry, , Volume: 32, Issue:6, 1989
Synthesis and structure-activity relationships of deazaxanthines: analogs of potent A1- and A2-adenosine receptor antagonists.Journal of medicinal chemistry, , May-13, Volume: 37, Issue:10, 1994
Effect of trifluoromethyl and other substituents on activity of xanthines at adenosine receptors.Journal of medicinal chemistry, , Sep-03, Volume: 36, Issue:18, 1993
Adenosine receptors: pharmacology, structure-activity relationships, and therapeutic potential.Journal of medicinal chemistry, , Feb-07, Volume: 35, Issue:3, 1992
Sulfur-containing 1,3-dialkylxanthine derivatives as selective antagonists at A1-adenosine receptors.Journal of medicinal chemistry, , Volume: 32, Issue:8, 1989
Effects of 8-phenyl and 8-cycloalkyl substituents on the activity of mono-, di-, and trisubstituted alkylxanthines with substitution at the 1-, 3-, and 7-positions.Journal of medicinal chemistry, , Volume: 32, Issue:6, 1989
Adenosine receptors: targets for future drugs.Journal of medicinal chemistry, , Volume: 25, Issue:3, 1982
Carbonic anhydrase inhibitors. Inhibition of mammalian isoforms I-XIV with a series of natural product polyphenols and phenolic acids.Bioorganic & medicinal chemistry, , Mar-15, Volume: 18, Issue:6, 2010
Carbonic anhydrase inhibitors: cloning, characterization, and inhibition studies of the cytosolic isozyme III with sulfonamides.Bioorganic & medicinal chemistry, , Dec-01, Volume: 15, Issue:23, 2007
[no title available]European journal of medicinal chemistry, , Jan-15, Volume: 186, 2020
Adenosine A2A receptor as a drug discovery target.Journal of medicinal chemistry, , May-08, Volume: 57, Issue:9, 2014
1,3-Dialkyl-substituted tetrahydropyrimido[1,2-f]purine-2,4-diones as multiple target drugs for the potential treatment of neurodegenerative diseases.Bioorganic & medicinal chemistry, , Dec-01, Volume: 21, Issue:23, 2013
2-Amino-5-benzoyl-4-phenylthiazoles: Development of potent and selective adenosine A1 receptor antagonists.Bioorganic & medicinal chemistry, , Mar-15, Volume: 18, Issue:6, 2010
1-alkyl-8-(piperazine-1-sulfonyl)phenylxanthines: development and characterization of adenosine A2B receptor antagonists and a new radioligand with subnanomolar affinity and subtype specificity.Journal of medicinal chemistry, , Jul-09, Volume: 52, Issue:13, 2009
Imidazo[2,1-i]purin-5-ones and related tricyclic water-soluble purine derivatives: potent A(2A)- and A(3)-adenosine receptor antagonists.Journal of medicinal chemistry, , Aug-01, Volume: 45, Issue:16, 2002
Structure-activity relationships at human and rat A2B adenosine receptors of xanthine derivatives substituted at the 1-, 3-, 7-, and 8-positions.Journal of medicinal chemistry, , May-23, Volume: 45, Issue:11, 2002
Synthesis and structure-activity relationships of deazaxanthines: analogs of potent A1- and A2-adenosine receptor antagonists.Journal of medicinal chemistry, , May-13, Volume: 37, Issue:10, 1994
Structure-activity relationships of 1,3-dialkylxanthine derivatives at rat A3 adenosine receptors.Journal of medicinal chemistry, , Sep-30, Volume: 37, Issue:20, 1994
Adenosine A1 antagonists. 3. Structure-activity relationships on amelioration against scopolamine- or N6-((R)-phenylisopropyl)adenosine-induced cognitive disturbance.Journal of medicinal chemistry, , Aug-20, Volume: 36, Issue:17, 1993
Effect of trifluoromethyl and other substituents on activity of xanthines at adenosine receptors.Journal of medicinal chemistry, , Sep-03, Volume: 36, Issue:18, 1993
Adenosine A1 antagonists. 2. Structure-activity relationships on diuretic activities and protective effects against acute renal failure.Journal of medicinal chemistry, , Aug-07, Volume: 35, Issue:16, 1992
(E)-1,3-dialkyl-7-methyl-8-(3,4,5-trimethoxystyryl)xanthines: potent and selective adenosine A2 antagonists.Journal of medicinal chemistry, , Jun-12, Volume: 35, Issue:12, 1992
Adenosine receptors: pharmacology, structure-activity relationships, and therapeutic potential.Journal of medicinal chemistry, , Feb-07, Volume: 35, Issue:3, 1992
8-(Dicyclopropylmethyl)-1,3-dipropylxanthine: a potent and selective adenosine A1 antagonist with renal protective and diuretic activities.Journal of medicinal chemistry, , Volume: 34, Issue:1, 1991
Imidazodiazepinediones: a new class of adenosine receptor antagonists.Journal of medicinal chemistry, , Volume: 33, Issue:10, 1990
Sulfur-containing 1,3-dialkylxanthine derivatives as selective antagonists at A1-adenosine receptors.Journal of medicinal chemistry, , Volume: 32, Issue:8, 1989
Effects of 8-phenyl and 8-cycloalkyl substituents on the activity of mono-, di-, and trisubstituted alkylxanthines with substitution at the 1-, 3-, and 7-positions.Journal of medicinal chemistry, , Volume: 32, Issue:6, 1989
Benzo[1,2-c:5,4-c']dipyrazoles: non-xanthine adenosine antagonists.Journal of medicinal chemistry, , Volume: 31, Issue:10, 1988
Adenosine receptors: targets for future drugs.Journal of medicinal chemistry, , Volume: 25, Issue:3, 1982
[no title available]European journal of medicinal chemistry, , Jan-15, Volume: 186, 2020
Novel multi-target directed ligands based on annelated xanthine scaffold with aromatic substituents acting on adenosine receptor and monoamine oxidase B. Synthesis, in vitro and in silico studies.Bioorganic & medicinal chemistry, , 04-01, Volume: 27, Issue:7, 2019
[no title available]European journal of medicinal chemistry, , Jan-05, Volume: 125, 2017
Discovery of 1,3-diethyl-7-methyl-8-(phenoxymethyl)-xanthine derivatives as novel adenosine ABioorganic & medicinal chemistry letters, , 12-15, Volume: 26, Issue:24, 2016
[no title available]Bioorganic & medicinal chemistry, , 11-01, Volume: 24, Issue:21, 2016
New Frontiers in Selective Human MAO-B Inhibitors.Journal of medicinal chemistry, , Sep-10, Volume: 58, Issue:17, 2015
1,3-Dialkyl-substituted tetrahydropyrimido[1,2-f]purine-2,4-diones as multiple target drugs for the potential treatment of neurodegenerative diseases.Bioorganic & medicinal chemistry, , Dec-01, Volume: 21, Issue:23, 2013
Dual inhibition of monoamine oxidase B and antagonism of the adenosine A(2A) receptor by (E,E)-8-(4-phenylbutadien-1-yl)caffeine analogues.Bioorganic & medicinal chemistry, , Sep-15, Volume: 16, Issue:18, 2008
Imidazo[2,1-i]purin-5-ones and related tricyclic water-soluble purine derivatives: potent A(2A)- and A(3)-adenosine receptor antagonists.Journal of medicinal chemistry, , Aug-01, Volume: 45, Issue:16, 2002
Synthesis and structure-activity relationships of deazaxanthines: analogs of potent A1- and A2-adenosine receptor antagonists.Journal of medicinal chemistry, , May-13, Volume: 37, Issue:10, 1994
Structure-activity relationships of 1,3-dialkylxanthine derivatives at rat A3 adenosine receptors.Journal of medicinal chemistry, , Sep-30, Volume: 37, Issue:20, 1994
Adenosine A1 antagonists. 3. Structure-activity relationships on amelioration against scopolamine- or N6-((R)-phenylisopropyl)adenosine-induced cognitive disturbance.Journal of medicinal chemistry, , Aug-20, Volume: 36, Issue:17, 1993
Effect of trifluoromethyl and other substituents on activity of xanthines at adenosine receptors.Journal of medicinal chemistry, , Sep-03, Volume: 36, Issue:18, 1993
8-Polycycloalkyl-1,3-dipropylxanthines as potent and selective antagonists for A1-adenosine receptors.Journal of medicinal chemistry, , Mar-06, Volume: 35, Issue:5, 1992
(E)-1,3-dialkyl-7-methyl-8-(3,4,5-trimethoxystyryl)xanthines: potent and selective adenosine A2 antagonists.Journal of medicinal chemistry, , Jun-12, Volume: 35, Issue:12, 1992
Adenosine receptors: pharmacology, structure-activity relationships, and therapeutic potential.Journal of medicinal chemistry, , Feb-07, Volume: 35, Issue:3, 1992
8-(Dicyclopropylmethyl)-1,3-dipropylxanthine: a potent and selective adenosine A1 antagonist with renal protective and diuretic activities.Journal of medicinal chemistry, , Volume: 34, Issue:1, 1991
4-Amino[1,2,4]triazolo[4,3-a]quinoxalines. A novel class of potent adenosine receptor antagonists and potential rapid-onset antidepressants.Journal of medicinal chemistry, , Volume: 33, Issue:8, 1990
Imidazodiazepinediones: a new class of adenosine receptor antagonists.Journal of medicinal chemistry, , Volume: 33, Issue:10, 1990
Effects of 8-phenyl and 8-cycloalkyl substituents on the activity of mono-, di-, and trisubstituted alkylxanthines with substitution at the 1-, 3-, and 7-positions.Journal of medicinal chemistry, , Volume: 32, Issue:6, 1989
Adenosine receptors: targets for future drugs.Journal of medicinal chemistry, , Volume: 25, Issue:3, 1982
Adenosine A2A receptor as a drug discovery target.Journal of medicinal chemistry, , May-08, Volume: 57, Issue:9, 2014
Thiazole and thiadiazole analogues as a novel class of adenosine receptor antagonists.Journal of medicinal chemistry, , Mar-01, Volume: 44, Issue:5, 2001
Derivatives of the triazoloquinazoline adenosine antagonist (CGS 15943) having high potency at the human A2B and A3 receptor subtypes.Journal of medicinal chemistry, , Jul-16, Volume: 41, Issue:15, 1998
Design, synthesis, and biological evaluation of a second generation of pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidines as potent and selective A2A adenosine receptor antagonists.Journal of medicinal chemistry, , Jun-04, Volume: 41, Issue:12, 1998
Tetrahydrobenzothiophenone derivatives as a novel class of adenosine receptor antagonists.Journal of medicinal chemistry, , Jan-19, Volume: 39, Issue:2, 1996
Derivatives of the triazoloquinazoline adenosine antagonist (CGS15943) are selective for the human A3 receptor subtype.Journal of medicinal chemistry, , Oct-11, Volume: 39, Issue:21, 1996
Pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine derivatives: potent and selective A(2A) adenosine antagonists.Journal of medicinal chemistry, , Mar-01, Volume: 39, Issue:5, 1996
Adenosine receptors: pharmacology, structure-activity relationships, and therapeutic potential.Journal of medicinal chemistry, , Feb-07, Volume: 35, Issue:3, 1992
4-Amino[1,2,4]triazolo[4,3-a]quinoxalines. A novel class of potent adenosine receptor antagonists and potential rapid-onset antidepressants.Journal of medicinal chemistry, , Volume: 33, Issue:8, 1990
Effect of trifluoromethyl and other substituents on activity of xanthines at adenosine receptors.Journal of medicinal chemistry, , Sep-03, Volume: 36, Issue:18, 1993
4-Amino[1,2,4]triazolo[4,3-a]quinoxalines. A novel class of potent adenosine receptor antagonists and potential rapid-onset antidepressants.Journal of medicinal chemistry, , Volume: 33, Issue:8, 1990
Imidazodiazepinediones: a new class of adenosine receptor antagonists.Journal of medicinal chemistry, , Volume: 33, Issue:10, 1990
Adenosine receptors: targets for future drugs.Journal of medicinal chemistry, , Volume: 25, Issue:3, 1982
Structure-activity relationships of 9-alkyladenine and ribose-modified adenosine derivatives at rat A3 adenosine receptors.Journal of medicinal chemistry, , May-12, Volume: 38, Issue:10, 1995
N6,9-disubstituted adenines: potent, selective antagonists at the A1 adenosine receptor.Journal of medicinal chemistry, , Volume: 34, Issue:9, 1991
1,8-disubstituted xanthine derivatives: synthesis of potent A2B-selective adenosine receptor antagonists.Journal of medicinal chemistry, , Mar-28, Volume: 45, Issue:7, 2002
Thiazole and thiadiazole analogues as a novel class of adenosine receptor antagonists.Journal of medicinal chemistry, , Mar-01, Volume: 44, Issue:5, 2001
Structure-activity relationships of 1,3-dialkylxanthine derivatives at rat A3 adenosine receptors.Journal of medicinal chemistry, , Sep-30, Volume: 37, Issue:20, 1994
(E)-1,3-dialkyl-7-methyl-8-(3,4,5-trimethoxystyryl)xanthines: potent and selective adenosine A2 antagonists.Journal of medicinal chemistry, , Jun-12, Volume: 35, Issue:12, 1992
Adenosine receptors: pharmacology, structure-activity relationships, and therapeutic potential.Journal of medicinal chemistry, , Feb-07, Volume: 35, Issue:3, 1992
Sulfur-containing 1,3-dialkylxanthine derivatives as selective antagonists at A1-adenosine receptors.Journal of medicinal chemistry, , Volume: 32, Issue:8, 1989
2-Substitution of N6-benzyladenosine-5'-uronamides enhances selectivity for A3 adenosine receptors.Journal of medicinal chemistry, , Oct-14, Volume: 37, Issue:21, 1994
Adenosine receptors: pharmacology, structure-activity relationships, and therapeutic potential.Journal of medicinal chemistry, , Feb-07, Volume: 35, Issue:3, 1992
Highly selective adenosine A2 receptor agonists in a series of N-alkylated 2-aminoadenosines.Journal of medicinal chemistry, , Volume: 34, Issue:8, 1991
Activity of N6-substituted 2-chloroadenosines at A1 and A2 adenosine receptors.Journal of medicinal chemistry, , Volume: 34, Issue:12, 1991
C2,N6-disubstituted adenosines: synthesis and structure-activity relationships.Journal of medicinal chemistry, , Volume: 32, Issue:8, 1989
N6-(arylalkyl)adenosines. Identification of N6-(9-fluorenylmethyl)adenosine as a highly potent agonist for the adenosine A2 receptor.Journal of medicinal chemistry, , Volume: 31, Issue:1, 1988
N6-cycloalkyladenosines. Potent, A1-selective adenosine agonists.Journal of medicinal chemistry, , Volume: 28, Issue:10, 1985
Adenosine receptors: targets for future drugs.Journal of medicinal chemistry, , Volume: 25, Issue:3, 1982
Chiral resolution and stereospecificity of 6-phenyl-4-phenylethynyl- 1,4-dihydropyridines as selective A(3) adenosine receptor antagonists.Journal of medicinal chemistry, , Aug-12, Volume: 42, Issue:16, 1999
Interaction of 1,4-dihydropyridine and pyridine derivatives with adenosine receptors: selectivity for A3 receptors.Journal of medicinal chemistry, , Jul-19, Volume: 39, Issue:15, 1996
Methanocarba analogues of purine nucleosides as potent and selective adenosine receptor agonists.Journal of medicinal chemistry, , Jun-01, Volume: 43, Issue:11, 2000
Synthesis and biological evaluation of N4-substituted imidazo- and v-triazolo[4,5-d]pyridazine nucleosides.Journal of medicinal chemistry, , Dec-10, Volume: 36, Issue:25, 1993
4-Amino[1,2,4]triazolo[4,3-a]quinoxalines. A novel class of potent adenosine receptor antagonists and potential rapid-onset antidepressants.Journal of medicinal chemistry, , Volume: 33, Issue:8, 1990
C2,N6-disubstituted adenosines: synthesis and structure-activity relationships.Journal of medicinal chemistry, , Volume: 32, Issue:8, 1989
[no title available]European journal of medicinal chemistry, , Jan-15, Volume: 186, 2020
2-Amino-5-benzoyl-4-phenylthiazoles: Development of potent and selective adenosine A1 receptor antagonists.Bioorganic & medicinal chemistry, , Mar-15, Volume: 18, Issue:6, 2010
Synthesis and biological evaluation of the enantiomers of the potent and selective A1-adenosine antagonist 1,3-dipropyl-8-[2-(5,6-epoxynorbonyl)]-xanthine.Journal of medicinal chemistry, , Jun-06, Volume: 40, Issue:12, 1997
8-Polycycloalkyl-1,3-dipropylxanthines as potent and selective antagonists for A1-adenosine receptors.Journal of medicinal chemistry, , Mar-06, Volume: 35, Issue:5, 1992
Adenosine receptors: pharmacology, structure-activity relationships, and therapeutic potential.Journal of medicinal chemistry, , Feb-07, Volume: 35, Issue:3, 1992
Ribose-modified adenosine analogues as potential partial agonists for the adenosine receptor.Journal of medicinal chemistry, , Sep-29, Volume: 38, Issue:20, 1995
N6,9-disubstituted adenines: potent, selective antagonists at the A1 adenosine receptor.Journal of medicinal chemistry, , Volume: 34, Issue:9, 1991
Synthesis and structure-activity relationships of deazaxanthines: analogs of potent A1- and A2-adenosine receptor antagonists.Journal of medicinal chemistry, , May-13, Volume: 37, Issue:10, 1994
Effects of 8-phenyl and 8-cycloalkyl substituents on the activity of mono-, di-, and trisubstituted alkylxanthines with substitution at the 1-, 3-, and 7-positions.Journal of medicinal chemistry, , Volume: 32, Issue:6, 1989
Benzo[1,2-c:5,4-c']dipyrazoles: non-xanthine adenosine antagonists.Journal of medicinal chemistry, , Volume: 31, Issue:10, 1988
N6,5'-Disubstituted adenosine derivatives as partial agonists for the human adenosine A3 receptor.Journal of medicinal chemistry, , Apr-22, Volume: 42, Issue:8, 1999
C2,N6-disubstituted adenosines: synthesis and structure-activity relationships.Journal of medicinal chemistry, , Volume: 32, Issue:8, 1989
N6-(arylalkyl)adenosines. Identification of N6-(9-fluorenylmethyl)adenosine as a highly potent agonist for the adenosine A2 receptor.Journal of medicinal chemistry, , Volume: 31, Issue:1, 1988
Adenosine receptors: pharmacology, structure-activity relationships, and therapeutic potential.Journal of medicinal chemistry, , Feb-07, Volume: 35, Issue:3, 1992
Analogues of 1,3-dipropyl-8-phenylxanthine: enhancement of selectivity at A1-adenosine receptors by aryl substituents.Journal of medicinal chemistry, , Volume: 29, Issue:8, 1986
Ribose-modified adenosine analogues as potential partial agonists for the adenosine receptor.Journal of medicinal chemistry, , Sep-29, Volume: 38, Issue:20, 1995
Adenosine receptors: pharmacology, structure-activity relationships, and therapeutic potential.Journal of medicinal chemistry, , Feb-07, Volume: 35, Issue:3, 1992
2-Alkynyl derivatives of adenosine and adenosine-5'-N-ethyluronamide as selective agonists at A2 adenosine receptors.Journal of medicinal chemistry, , Jun-26, Volume: 35, Issue:13, 1992
Highly selective adenosine A2 receptor agonists in a series of N-alkylated 2-aminoadenosines.Journal of medicinal chemistry, , Volume: 34, Issue:8, 1991
Activity of N6-substituted 2-chloroadenosines at A1 and A2 adenosine receptors.Journal of medicinal chemistry, , Volume: 34, Issue:12, 1991
4-Amino[1,2,4]triazolo[4,3-a]quinoxalines. A novel class of potent adenosine receptor antagonists and potential rapid-onset antidepressants.Journal of medicinal chemistry, , Volume: 33, Issue:8, 1990
C2,N6-disubstituted adenosines: synthesis and structure-activity relationships.Journal of medicinal chemistry, , Volume: 32, Issue:8, 1989
N6-(arylalkyl)adenosines. Identification of N6-(9-fluorenylmethyl)adenosine as a highly potent agonist for the adenosine A2 receptor.Journal of medicinal chemistry, , Volume: 31, Issue:1, 1988
Adenosine receptor agonists: synthesis and biological evaluation of 1-deaza analogues of adenosine derivatives.Journal of medicinal chemistry, , Volume: 31, Issue:6, 1988
N6-[2-(3,5-dimethoxyphenyl)-2-(2-methylphenyl)ethyl]adenosine and its uronamide derivatives. Novel adenosine agonists with both high affinity and high selectivity for the adenosine A2 receptor.Journal of medicinal chemistry, , Volume: 31, Issue:7, 1988
N6-cycloalkyladenosines. Potent, A1-selective adenosine agonists.Journal of medicinal chemistry, , Volume: 28, Issue:10, 1985
C4-substituted 1-beta-D-ribofuranosylpyrazolo[3,4-d]pyrimidines as adenosine agonist analogues.Journal of medicinal chemistry, , Volume: 26, Issue:11, 1983
Adenosine receptors: targets for future drugs.Journal of medicinal chemistry, , Volume: 25, Issue:3, 1982
Design and in Vivo Characterization of AJournal of medicinal chemistry, , 02-14, Volume: 62, Issue:3, 2019
Structure-activity relationships of N6-benzyladenosine-5'-uronamides as A3-selective adenosine agonists.Journal of medicinal chemistry, , Mar-04, Volume: 37, Issue:5, 1994
N6-substituted N-alkyladenosine-5'-uronamides: bifunctional ligands having recognition groups for A1 and A2 adenosine receptors.Journal of medicinal chemistry, , Volume: 29, Issue:9, 1986
1,3-Dialkyl-substituted tetrahydropyrimido[1,2-f]purine-2,4-diones as multiple target drugs for the potential treatment of neurodegenerative diseases.Bioorganic & medicinal chemistry, , Dec-01, Volume: 21, Issue:23, 2013
Adenosine receptors: pharmacology, structure-activity relationships, and therapeutic potential.Journal of medicinal chemistry, , Feb-07, Volume: 35, Issue:3, 1992
Adenosine receptors: pharmacology, structure-activity relationships, and therapeutic potential.Journal of medicinal chemistry, , Feb-07, Volume: 35, Issue:3, 1992
Activity of N6-substituted 2-chloroadenosines at A1 and A2 adenosine receptors.Journal of medicinal chemistry, , Volume: 34, Issue:12, 1991
4-Amino[1,2,4]triazolo[4,3-a]quinoxalines. A novel class of potent adenosine receptor antagonists and potential rapid-onset antidepressants.Journal of medicinal chemistry, , Volume: 33, Issue:8, 1990
N6-phenyladenosines: pronounced effect of phenyl substituents on affinity for A2 adenosine receptors.Journal of medicinal chemistry, , Volume: 30, Issue:5, 1987
Structure-activity relationships of 1,3-dialkylxanthine derivatives at rat A3 adenosine receptors.Journal of medicinal chemistry, , Sep-30, Volume: 37, Issue:20, 1994
Effects of 8-phenyl and 8-cycloalkyl substituents on the activity of mono-, di-, and trisubstituted alkylxanthines with substitution at the 1-, 3-, and 7-positions.Journal of medicinal chemistry, , Volume: 32, Issue:6, 1989
8-Aryl-and 8-cycloalkyl-1,3-dipropylxanthines: further potent and selective antagonists for A1-adenosine receptors.Journal of medicinal chemistry, , Volume: 31, Issue:3, 1988
Analogues of 1,3-dipropyl-8-phenylxanthine: enhancement of selectivity at A1-adenosine receptors by aryl substituents.Journal of medicinal chemistry, , Volume: 29, Issue:8, 1986
Medicinal chemistry of A₃ adenosine receptor modulators: pharmacological activities and therapeutic implications.Journal of medicinal chemistry, , Jun-28, Volume: 55, Issue:12, 2012
Design of (N)-methanocarba adenosine 5'-uronamides as species-independent A3 receptor-selective agonists.Bioorganic & medicinal chemistry letters, , May-01, Volume: 18, Issue:9, 2008
Structure-activity relationships and molecular modeling of 3, 5-diacyl-2,4-dialkylpyridine derivatives as selective A3 adenosine receptor antagonists.Journal of medicinal chemistry, , Aug-13, Volume: 41, Issue:17, 1998
Novel N6-(substituted-phenylcarbamoyl)adenosine-5'-uronamides as potent agonists for A3 adenosine receptors.Journal of medicinal chemistry, , Feb-02, Volume: 39, Issue:3, 1996
Structure-activity relationships of 9-alkyladenine and ribose-modified adenosine derivatives at rat A3 adenosine receptors.Journal of medicinal chemistry, , May-12, Volume: 38, Issue:10, 1995
2-Substitution of N6-benzyladenosine-5'-uronamides enhances selectivity for A3 adenosine receptors.Journal of medicinal chemistry, , Oct-14, Volume: 37, Issue:21, 1994
Structure-activity relationships of N6-benzyladenosine-5'-uronamides as A3-selective adenosine agonists.Journal of medicinal chemistry, , Mar-04, Volume: 37, Issue:5, 1994
N-cycloalkyl derivatives of adenosine and 1-deazaadenosine as agonists and partial agonists of the A(1) adenosine receptor.Journal of medicinal chemistry, , Jan-27, Volume: 43, Issue:2, 2000
Methanocarba analogues of purine nucleosides as potent and selective adenosine receptor agonists.Journal of medicinal chemistry, , Jun-01, Volume: 43, Issue:11, 2000
2-[N'-(3-arylallylidene)hydrazino]adenosines showing A2a adenosine agonist properties and vasodilation activity.Journal of medicinal chemistry, , Sep-01, Volume: 38, Issue:18, 1995
2-Aralkynyl and 2-heteroalkynyl derivatives of adenosine-5'-N-ethyluronamide as selective A2a adenosine receptor agonists.Journal of medicinal chemistry, , Apr-28, Volume: 38, Issue:9, 1995
2-Substitution of N6-benzyladenosine-5'-uronamides enhances selectivity for A3 adenosine receptors.Journal of medicinal chemistry, , Oct-14, Volume: 37, Issue:21, 1994
Adenosine receptors: pharmacology, structure-activity relationships, and therapeutic potential.Journal of medicinal chemistry, , Feb-07, Volume: 35, Issue:3, 1992
Activity of N6-substituted 2-chloroadenosines at A1 and A2 adenosine receptors.Journal of medicinal chemistry, , Volume: 34, Issue:12, 1991
Tetrahydrobenzothiophenone derivatives as a novel class of adenosine receptor antagonists.Journal of medicinal chemistry, , Jan-19, Volume: 39, Issue:2, 1996
Adenosine receptors: pharmacology, structure-activity relationships, and therapeutic potential.Journal of medicinal chemistry, , Feb-07, Volume: 35, Issue:3, 1992
4-Amino[1,2,4]triazolo[4,3-a]quinoxalines. A novel class of potent adenosine receptor antagonists and potential rapid-onset antidepressants.Journal of medicinal chemistry, , Volume: 33, Issue:8, 1990
Design, synthesis, and structure-activity relationships of 1-,3-,8-, and 9-substituted-9-deazaxanthines at the human A2B adenosine receptor.Journal of medicinal chemistry, , Jan-12, Volume: 49, Issue:1, 2006
Structure-activity relationships of 1,3-dialkylxanthine derivatives at rat A3 adenosine receptors.Journal of medicinal chemistry, , Sep-30, Volume: 37, Issue:20, 1994
Adenosine receptors: pharmacology, structure-activity relationships, and therapeutic potential.Journal of medicinal chemistry, , Feb-07, Volume: 35, Issue:3, 1992
Sulfur-containing 1,3-dialkylxanthine derivatives as selective antagonists at A1-adenosine receptors.Journal of medicinal chemistry, , Volume: 32, Issue:8, 1989
Synthesis and structure-activity relationships of deazaxanthines: analogs of potent A1- and A2-adenosine receptor antagonists.Journal of medicinal chemistry, , May-13, Volume: 37, Issue:10, 1994
Effect of trifluoromethyl and other substituents on activity of xanthines at adenosine receptors.Journal of medicinal chemistry, , Sep-03, Volume: 36, Issue:18, 1993
Sulfur-containing 1,3-dialkylxanthine derivatives as selective antagonists at A1-adenosine receptors.Journal of medicinal chemistry, , Volume: 32, Issue:8, 1989
Effects of 8-phenyl and 8-cycloalkyl substituents on the activity of mono-, di-, and trisubstituted alkylxanthines with substitution at the 1-, 3-, and 7-positions.Journal of medicinal chemistry, , Volume: 32, Issue:6, 1989
8-Aryl-and 8-cycloalkyl-1,3-dipropylxanthines: further potent and selective antagonists for A1-adenosine receptors.Journal of medicinal chemistry, , Volume: 31, Issue:3, 1988
Analogues of 1,3-dipropyl-8-phenylxanthine: enhancement of selectivity at A1-adenosine receptors by aryl substituents.Journal of medicinal chemistry, , Volume: 29, Issue:8, 1986
Adenosine A1 antagonists. 3. Structure-activity relationships on amelioration against scopolamine- or N6-((R)-phenylisopropyl)adenosine-induced cognitive disturbance.Journal of medicinal chemistry, , Aug-20, Volume: 36, Issue:17, 1993
8-Polycycloalkyl-1,3-dipropylxanthines as potent and selective antagonists for A1-adenosine receptors.Journal of medicinal chemistry, , Mar-06, Volume: 35, Issue:5, 1992
Adenosine receptors: pharmacology, structure-activity relationships, and therapeutic potential.Journal of medicinal chemistry, , Feb-07, Volume: 35, Issue:3, 1992
8-(Dicyclopropylmethyl)-1,3-dipropylxanthine: a potent and selective adenosine A1 antagonist with renal protective and diuretic activities.Journal of medicinal chemistry, , Volume: 34, Issue:1, 1991
Adenosine A1 antagonists. 3. Structure-activity relationships on amelioration against scopolamine- or N6-((R)-phenylisopropyl)adenosine-induced cognitive disturbance.Journal of medicinal chemistry, , Aug-20, Volume: 36, Issue:17, 1993
Adenosine receptors: pharmacology, structure-activity relationships, and therapeutic potential.Journal of medicinal chemistry, , Feb-07, Volume: 35, Issue:3, 1992
Fluorosulfonyl-substituted xanthines as selective irreversible antagonists for the A(1)-adenosine receptor.Journal of medicinal chemistry, , Dec-28, Volume: 43, Issue:26, 2000
Substituted 1,3-dipropylxanthines as irreversible antagonists of A1 adenosine receptors.Journal of medicinal chemistry, , Aug-19, Volume: 37, Issue:17, 1994
Nucleosides and nucleotides. 112. 2-(1-Hexyn-1-yl)adenosine-5'-uronamides: a new entry of selective A2 adenosine receptor agonists with potent antihypertensive activity.Journal of medicinal chemistry, , Jul-24, Volume: 35, Issue:15, 1992
Nucleosides and nucleotides. 107. 2-(cycloalkylalkynyl)adenosines: adenosine A2 receptor agonists with potent antihypertensive effects.Journal of medicinal chemistry, , Jun-12, Volume: 35, Issue:12, 1992
Adenosine receptors: pharmacology, structure-activity relationships, and therapeutic potential.Journal of medicinal chemistry, , Feb-07, Volume: 35, Issue:3, 1992
2-Alkynyl derivatives of adenosine and adenosine-5'-N-ethyluronamide as selective agonists at A2 adenosine receptors.Journal of medicinal chemistry, , Jun-26, Volume: 35, Issue:13, 1992
Synthesis and structure-activity relationships of deazaxanthines: analogs of potent A1- and A2-adenosine receptor antagonists.Journal of medicinal chemistry, , May-13, Volume: 37, Issue:10, 1994
Effects of 8-phenyl and 8-cycloalkyl substituents on the activity of mono-, di-, and trisubstituted alkylxanthines with substitution at the 1-, 3-, and 7-positions.Journal of medicinal chemistry, , Volume: 32, Issue:6, 1989
2-alkenyl and 2-alkyl derivatives of adenosine and adenosine-5'-N-ethyluronamide: different affinity and selectivity of E- and Z-diastereomers at A2A adenosine receptors.Journal of medicinal chemistry, , Oct-11, Volume: 39, Issue:21, 1996
2-Aralkynyl and 2-heteroalkynyl derivatives of adenosine-5'-N-ethyluronamide as selective A2a adenosine receptor agonists.Journal of medicinal chemistry, , Apr-28, Volume: 38, Issue:9, 1995
Nucleosides and nucleotides. 112. 2-(1-Hexyn-1-yl)adenosine-5'-uronamides: a new entry of selective A2 adenosine receptor agonists with potent antihypertensive activity.Journal of medicinal chemistry, , Jul-24, Volume: 35, Issue:15, 1992
2-Alkynyl derivatives of adenosine and adenosine-5'-N-ethyluronamide as selective agonists at A2 adenosine receptors.Journal of medicinal chemistry, , Jun-26, Volume: 35, Issue:13, 1992
Synthesis and structure-activity relationships of deazaxanthines: analogs of potent A1- and A2-adenosine receptor antagonists.Journal of medicinal chemistry, , May-13, Volume: 37, Issue:10, 1994
Effect of trifluoromethyl and other substituents on activity of xanthines at adenosine receptors.Journal of medicinal chemistry, , Sep-03, Volume: 36, Issue:18, 1993
(E)-1,3-dialkyl-7-methyl-8-(3,4,5-trimethoxystyryl)xanthines: potent and selective adenosine A2 antagonists.Journal of medicinal chemistry, , Jun-12, Volume: 35, Issue:12, 1992
8-(Dicyclopropylmethyl)-1,3-dipropylxanthine: a potent and selective adenosine A1 antagonist with renal protective and diuretic activities.Journal of medicinal chemistry, , Volume: 34, Issue:1, 1991
Sulfur-containing 1,3-dialkylxanthine derivatives as selective antagonists at A1-adenosine receptors.Journal of medicinal chemistry, , Volume: 32, Issue:8, 1989
Effects of 8-phenyl and 8-cycloalkyl substituents on the activity of mono-, di-, and trisubstituted alkylxanthines with substitution at the 1-, 3-, and 7-positions.Journal of medicinal chemistry, , Volume: 32, Issue:6, 1989
Benzo[1,2-c:5,4-c']dipyrazoles: non-xanthine adenosine antagonists.Journal of medicinal chemistry, , Volume: 31, Issue:10, 1988
8-Aryl-and 8-cycloalkyl-1,3-dipropylxanthines: further potent and selective antagonists for A1-adenosine receptors.Journal of medicinal chemistry, , Volume: 31, Issue:3, 1988
[no title available]Bioorganic & medicinal chemistry letters, , 08-15, Volume: 30, Issue:16, 2020
Antioxidant-Conjugated 1,2,4-Triazolo[4,3-Journal of medicinal chemistry, , 09-26, Volume: 62, Issue:18, 2019
Synthesis and biological evaluation of a new series of 1,2,4-triazolo[1,5-a]-1,3,5-triazines as human A(2A) adenosine receptor antagonists with improved water solubility.Journal of medicinal chemistry, , Feb-10, Volume: 54, Issue:3, 2011
2-Amino-N-pyrimidin-4-ylacetamides as A2A receptor antagonists: 2. Reduction of hERG activity, observed species selectivity, and structure-activity relationships.Journal of medicinal chemistry, , Mar-27, Volume: 51, Issue:6, 2008
Novel diamino derivatives of [1,2,4]triazolo[1,5-a][1,3,5]triazine as potent and selective adenosine A2a receptor antagonists.Journal of medicinal chemistry, , Mar-24, Volume: 48, Issue:6, 2005
Piperazine derivatives of [1,2,4]triazolo[1,5-a][1,3,5]triazine as potent and selective adenosine A2a receptor antagonists.Journal of medicinal chemistry, , Aug-12, Volume: 47, Issue:17, 2004
Tetrahydrobenzothiophenone derivatives as a novel class of adenosine receptor antagonists.Journal of medicinal chemistry, , Jan-19, Volume: 39, Issue:2, 1996
Novel diamino derivatives of [1,2,4]triazolo[1,5-a][1,3,5]triazine as potent and selective adenosine A2a receptor antagonists.Journal of medicinal chemistry, , Mar-24, Volume: 48, Issue:6, 2005
Synthesis of alkyne derivatives of a novel triazolopyrazine as A(2A) adenosine receptor antagonists.Bioorganic & medicinal chemistry letters, , Feb-01, Volume: 15, Issue:3, 2005
Piperazine derivatives of [1,2,4]triazolo[1,5-a][1,3,5]triazine as potent and selective adenosine A2a receptor antagonists.Journal of medicinal chemistry, , Aug-12, Volume: 47, Issue:17, 2004
Triamino derivatives of triazolotriazine and triazolopyrimidine as adenosine A2a receptor antagonists.Bioorganic & medicinal chemistry letters, , Oct-04, Volume: 14, Issue:19, 2004
Studies on adenosine A2a receptor antagonists: comparison of three core heterocycles.Bioorganic & medicinal chemistry letters, , Oct-04, Volume: 14, Issue:19, 2004
Design, synthesis, and biological evaluation of C9- and C2-substituted pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidines as new A2A and A3 adenosine receptors antagonists.Journal of medicinal chemistry, , Mar-27, Volume: 46, Issue:7, 2003
Design, synthesis, and biological evaluation of a second generation of pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidines as potent and selective A2A adenosine receptor antagonists.Journal of medicinal chemistry, , Jun-04, Volume: 41, Issue:12, 1998
Tetrahydrobenzothiophenone derivatives as a novel class of adenosine receptor antagonists.Journal of medicinal chemistry, , Jan-19, Volume: 39, Issue:2, 1996
Pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine derivatives: potent and selective A(2A) adenosine antagonists.Journal of medicinal chemistry, , Mar-01, Volume: 39, Issue:5, 1996
Medicinal chemistry of A₃ adenosine receptor modulators: pharmacological activities and therapeutic implications.Journal of medicinal chemistry, , Jun-28, Volume: 55, Issue:12, 2012
Structure-activity relationships of 4-(phenylethynyl)-6-phenyl-1,4-dihydropyridines as highly selective A3 adenosine receptor antagonists.Journal of medicinal chemistry, , Aug-01, Volume: 40, Issue:16, 1997
Derivatives of the triazoloquinazoline adenosine antagonist (CGS15943) are selective for the human A3 receptor subtype.Journal of medicinal chemistry, , Oct-11, Volume: 39, Issue:21, 1996
1,2,4-Triazolo[5,1-i]purine derivatives as highly potent and selective human adenosine A(3) receptor ligands.Journal of medicinal chemistry, , Aug-15, Volume: 45, Issue:17, 2002
Pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine derivatives as highly potent and selective human A(3) adenosine receptor antagonists.Journal of medicinal chemistry, , Nov-04, Volume: 42, Issue:22, 1999
Derivatives of the triazoloquinazoline adenosine antagonist (CGS 15943) having high potency at the human A2B and A3 receptor subtypes.Journal of medicinal chemistry, , Jul-16, Volume: 41, Issue:15, 1998
Structure-activity relationships of 4-(phenylethynyl)-6-phenyl-1,4-dihydropyridines as highly selective A3 adenosine receptor antagonists.Journal of medicinal chemistry, , Aug-01, Volume: 40, Issue:16, 1997
Derivatives of the triazoloquinazoline adenosine antagonist (CGS15943) are selective for the human A3 receptor subtype.Journal of medicinal chemistry, , Oct-11, Volume: 39, Issue:21, 1996
Design and in Vivo Characterization of AJournal of medicinal chemistry, , 02-14, Volume: 62, Issue:3, 2019
[no title available]Journal of medicinal chemistry, , 12-22, Volume: 59, Issue:24, 2016
Synthesis and structure-activity relationships of 2-hydrazinyladenosine derivatives as A(2A) adenosine receptor ligands.Bioorganic & medicinal chemistry, , Jan-15, Volume: 21, Issue:2, 2013
Optimization of adenosine 5'-carboxamide derivatives as adenosine receptor agonists using structure-based ligand design and fragment screening.Journal of medicinal chemistry, , May-10, Volume: 55, Issue:9, 2012
Development of Polar Adenosine A2A Receptor Agonists for Inflammatory Bowel Disease: Synergism with A2B Antagonists.ACS medicinal chemistry letters, , Dec-08, Volume: 2, Issue:12, 2011
Synthesis and biological activity of tricyclic cycloalkylimidazo-, pyrimido- and diazepinopurinediones.European journal of medicinal chemistry, , Volume: 46, Issue:9, 2011
Nucleosides and nucleotides. 177. 9-(6,7-dideoxy-beta-D-allo-hept-5- ynofuranosyl)adenine: a selective and potent ligand for P3 purinoceptor-like protein.Journal of medicinal chemistry, , Jul-16, Volume: 41, Issue:15, 1998
2-alkenyl and 2-alkyl derivatives of adenosine and adenosine-5'-N-ethyluronamide: different affinity and selectivity of E- and Z-diastereomers at A2A adenosine receptors.Journal of medicinal chemistry, , Oct-11, Volume: 39, Issue:21, 1996
2-[N'-(3-arylallylidene)hydrazino]adenosines showing A2a adenosine agonist properties and vasodilation activity.Journal of medicinal chemistry, , Sep-01, Volume: 38, Issue:18, 1995
2-Aralkynyl and 2-heteroalkynyl derivatives of adenosine-5'-N-ethyluronamide as selective A2a adenosine receptor agonists.Journal of medicinal chemistry, , Apr-28, Volume: 38, Issue:9, 1995
Structure-activity relationships of N6-benzyladenosine-5'-uronamides as A3-selective adenosine agonists.Journal of medicinal chemistry, , Mar-04, Volume: 37, Issue:5, 1994
Nucleosides and nucleotides. 112. 2-(1-Hexyn-1-yl)adenosine-5'-uronamides: a new entry of selective A2 adenosine receptor agonists with potent antihypertensive activity.Journal of medicinal chemistry, , Jul-24, Volume: 35, Issue:15, 1992
Adenosine receptors: pharmacology, structure-activity relationships, and therapeutic potential.Journal of medicinal chemistry, , Feb-07, Volume: 35, Issue:3, 1992
2-Alkynyl derivatives of adenosine and adenosine-5'-N-ethyluronamide as selective agonists at A2 adenosine receptors.Journal of medicinal chemistry, , Jun-26, Volume: 35, Issue:13, 1992
Highly selective adenosine A2 receptor agonists in a series of N-alkylated 2-aminoadenosines.Journal of medicinal chemistry, , Volume: 34, Issue:8, 1991
4-Amino[1,2,4]triazolo[4,3-a]quinoxalines. A novel class of potent adenosine receptor antagonists and potential rapid-onset antidepressants.Journal of medicinal chemistry, , Volume: 33, Issue:8, 1990
Adenosine receptor agonists: synthesis and biological evaluation of 1-deaza analogues of adenosine derivatives.Journal of medicinal chemistry, , Volume: 31, Issue:6, 1988
N6-[2-(3,5-dimethoxyphenyl)-2-(2-methylphenyl)ethyl]adenosine and its uronamide derivatives. Novel adenosine agonists with both high affinity and high selectivity for the adenosine A2 receptor.Journal of medicinal chemistry, , Volume: 31, Issue:7, 1988
N6-phenyladenosines: pronounced effect of phenyl substituents on affinity for A2 adenosine receptors.Journal of medicinal chemistry, , Volume: 30, Issue:5, 1987
N6-substituted N-alkyladenosine-5'-uronamides: bifunctional ligands having recognition groups for A1 and A2 adenosine receptors.Journal of medicinal chemistry, , Volume: 29, Issue:9, 1986
N6-cycloalkyladenosines. Potent, A1-selective adenosine agonists.Journal of medicinal chemistry, , Volume: 28, Issue:10, 1985
[no title available]Bioorganic & medicinal chemistry letters, , 08-15, Volume: 30, Issue:16, 2020
1,3,7-Triethyl-substituted xanthines--possess nanomolar affinity for the adenosine A1 receptor.Bioorganic & medicinal chemistry, , Oct-15, Volume: 23, Issue:20, 2015
N-cycloalkyl derivatives of adenosine and 1-deazaadenosine as agonists and partial agonists of the A(1) adenosine receptor.Journal of medicinal chemistry, , Jan-27, Volume: 43, Issue:2, 2000
Methanocarba analogues of purine nucleosides as potent and selective adenosine receptor agonists.Journal of medicinal chemistry, , Jun-01, Volume: 43, Issue:11, 2000
N6,5'-Disubstituted adenosine derivatives as partial agonists for the human adenosine A3 receptor.Journal of medicinal chemistry, , Apr-22, Volume: 42, Issue:8, 1999
N6,C8-distributed adenosine derivatives as partial agonists for adenosine A1 receptors.Journal of medicinal chemistry, , Mar-29, Volume: 39, Issue:7, 1996
Ribose-modified adenosine analogues as potential partial agonists for the adenosine receptor.Journal of medicinal chemistry, , Sep-29, Volume: 38, Issue:20, 1995
2-Substitution of N6-benzyladenosine-5'-uronamides enhances selectivity for A3 adenosine receptors.Journal of medicinal chemistry, , Oct-14, Volume: 37, Issue:21, 1994
Adenosine receptors: pharmacology, structure-activity relationships, and therapeutic potential.Journal of medicinal chemistry, , Feb-07, Volume: 35, Issue:3, 1992
2-Alkynyl derivatives of adenosine and adenosine-5'-N-ethyluronamide as selective agonists at A2 adenosine receptors.Journal of medicinal chemistry, , Jun-26, Volume: 35, Issue:13, 1992
Highly selective adenosine A2 receptor agonists in a series of N-alkylated 2-aminoadenosines.Journal of medicinal chemistry, , Volume: 34, Issue:8, 1991
Activity of N6-substituted 2-chloroadenosines at A1 and A2 adenosine receptors.Journal of medicinal chemistry, , Volume: 34, Issue:12, 1991
C2,N6-disubstituted adenosines: synthesis and structure-activity relationships.Journal of medicinal chemistry, , Volume: 32, Issue:8, 1989
N6-(arylalkyl)adenosines. Identification of N6-(9-fluorenylmethyl)adenosine as a highly potent agonist for the adenosine A2 receptor.Journal of medicinal chemistry, , Volume: 31, Issue:1, 1988
Adenosine receptor agonists: synthesis and biological evaluation of 1-deaza analogues of adenosine derivatives.Journal of medicinal chemistry, , Volume: 31, Issue:6, 1988
N6-[2-(3,5-dimethoxyphenyl)-2-(2-methylphenyl)ethyl]adenosine and its uronamide derivatives. Novel adenosine agonists with both high affinity and high selectivity for the adenosine A2 receptor.Journal of medicinal chemistry, , Volume: 31, Issue:7, 1988
N6-cycloalkyladenosines. Potent, A1-selective adenosine agonists.Journal of medicinal chemistry, , Volume: 28, Issue:10, 1985
Medicinal chemistry of A₃ adenosine receptor modulators: pharmacological activities and therapeutic implications.Journal of medicinal chemistry, , Jun-28, Volume: 55, Issue:12, 2012
Design of (N)-methanocarba adenosine 5'-uronamides as species-independent A3 receptor-selective agonists.Bioorganic & medicinal chemistry letters, , May-01, Volume: 18, Issue:9, 2008
N6-substituted D-4'-thioadenosine-5'-methyluronamides: potent and selective agonists at the human A3 adenosine receptor.Journal of medicinal chemistry, , Aug-28, Volume: 46, Issue:18, 2003
Structure-activity relationships and molecular modeling of 3, 5-diacyl-2,4-dialkylpyridine derivatives as selective A3 adenosine receptor antagonists.Journal of medicinal chemistry, , Aug-13, Volume: 41, Issue:17, 1998
2-Substitution of N6-benzyladenosine-5'-uronamides enhances selectivity for A3 adenosine receptors.Journal of medicinal chemistry, , Oct-14, Volume: 37, Issue:21, 1994
Evaluation of molecular modeling of agonist binding in light of the crystallographic structure of an agonist-bound A₂A adenosine receptor.Journal of medicinal chemistry, , Jan-12, Volume: 55, Issue:1, 2012
2-Substitution of N6-benzyladenosine-5'-uronamides enhances selectivity for A3 adenosine receptors.Journal of medicinal chemistry, , Oct-14, Volume: 37, Issue:21, 1994
Adenosine receptors: pharmacology, structure-activity relationships, and therapeutic potential.Journal of medicinal chemistry, , Feb-07, Volume: 35, Issue:3, 1992
Adenosine A2A receptor as a drug discovery target.Journal of medicinal chemistry, , May-08, Volume: 57, Issue:9, 2014
Evaluation of molecular modeling of agonist binding in light of the crystallographic structure of an agonist-bound A₂A adenosine receptor.Journal of medicinal chemistry, , Jan-12, Volume: 55, Issue:1, 2012
Development of Polar Adenosine A2A Receptor Agonists for Inflammatory Bowel Disease: Synergism with A2B Antagonists.ACS medicinal chemistry letters, , Dec-08, Volume: 2, Issue:12, 2011
2-[N'-(3-arylallylidene)hydrazino]adenosines showing A2a adenosine agonist properties and vasodilation activity.Journal of medicinal chemistry, , Sep-01, Volume: 38, Issue:18, 1995
2-Aralkynyl and 2-heteroalkynyl derivatives of adenosine-5'-N-ethyluronamide as selective A2a adenosine receptor agonists.Journal of medicinal chemistry, , Apr-28, Volume: 38, Issue:9, 1995
2-Substitution of N6-benzyladenosine-5'-uronamides enhances selectivity for A3 adenosine receptors.Journal of medicinal chemistry, , Oct-14, Volume: 37, Issue:21, 1994
Nucleosides and nucleotides. 112. 2-(1-Hexyn-1-yl)adenosine-5'-uronamides: a new entry of selective A2 adenosine receptor agonists with potent antihypertensive activity.Journal of medicinal chemistry, , Jul-24, Volume: 35, Issue:15, 1992
Nucleosides and nucleotides. 107. 2-(cycloalkylalkynyl)adenosines: adenosine A2 receptor agonists with potent antihypertensive effects.Journal of medicinal chemistry, , Jun-12, Volume: 35, Issue:12, 1992
Adenosine receptors: pharmacology, structure-activity relationships, and therapeutic potential.Journal of medicinal chemistry, , Feb-07, Volume: 35, Issue:3, 1992
[no title available]European journal of medicinal chemistry, , Jan-15, Volume: 186, 2020
Synthesis, CoMFA analysis, and receptor docking of 3,5-diacyl-2, 4-dialkylpyridine derivatives as selective A3 adenosine receptor antagonists.Journal of medicinal chemistry, , Feb-25, Volume: 42, Issue:4, 1999
Novel multi-target directed ligands based on annelated xanthine scaffold with aromatic substituents acting on adenosine receptor and monoamine oxidase B. Synthesis, in vitro and in silico studies.Bioorganic & medicinal chemistry, , 04-01, Volume: 27, Issue:7, 2019
8-Substituted 2-alkynyl-N(9)-propargyladenines as A2A adenosine receptor antagonists.Bioorganic & medicinal chemistry, , Jun-15, Volume: 22, Issue:12, 2014
1,3-Dialkyl-substituted tetrahydropyrimido[1,2-f]purine-2,4-diones as multiple target drugs for the potential treatment of neurodegenerative diseases.Bioorganic & medicinal chemistry, , Dec-01, Volume: 21, Issue:23, 2013
Dual targeting of adenosine A(2A) receptors and monoamine oxidase B by 4H-3,1-benzothiazin-4-ones.Journal of medicinal chemistry, , Jun-13, Volume: 56, Issue:11, 2013
Identification of novel, water-soluble, 2-amino-N-pyrimidin-4-yl acetamides as A2A receptor antagonists with in vivo efficacy.Journal of medicinal chemistry, , Feb-14, Volume: 51, Issue:3, 2008
Dual inhibition of monoamine oxidase B and antagonism of the adenosine A(2A) receptor by (E,E)-8-(4-phenylbutadien-1-yl)caffeine analogues.Bioorganic & medicinal chemistry, , Sep-15, Volume: 16, Issue:18, 2008
AJournal of medicinal chemistry, , 04-25, Volume: 62, Issue:8, 2019
Preparation, properties, reactions, and adenosine receptor affinities of sulfophenylxanthine nitrophenyl esters: toward the development of sulfonic acid prodrugs with peroral bioavailability.Journal of medicinal chemistry, , Feb-12, Volume: 47, Issue:4, 2004
Activity of N6-substituted 2-chloroadenosines at A1 and A2 adenosine receptors.Journal of medicinal chemistry, , Volume: 34, Issue:12, 1991
4-Amino[1,2,4]triazolo[4,3-a]quinoxalines. A novel class of potent adenosine receptor antagonists and potential rapid-onset antidepressants.Journal of medicinal chemistry, , Volume: 33, Issue:8, 1990
N6-cycloalkyladenosines. Potent, A1-selective adenosine agonists.Journal of medicinal chemistry, , Volume: 28, Issue:10, 1985
Adenosine receptors: targets for future drugs.Journal of medicinal chemistry, , Volume: 25, Issue:3, 1982
1,3,7-Triethyl-substituted xanthines--possess nanomolar affinity for the adenosine A1 receptor.Bioorganic & medicinal chemistry, , Oct-15, Volume: 23, Issue:20, 2015
1,3-Dialkyl-substituted tetrahydropyrimido[1,2-f]purine-2,4-diones as multiple target drugs for the potential treatment of neurodegenerative diseases.Bioorganic & medicinal chemistry, , Dec-01, Volume: 21, Issue:23, 2013
Dual targeting of adenosine A(2A) receptors and monoamine oxidase B by 4H-3,1-benzothiazin-4-ones.Journal of medicinal chemistry, , Jun-13, Volume: 56, Issue:11, 2013
Structure-activity relationships of 1,3-dialkylxanthine derivatives at rat A3 adenosine receptors.Journal of medicinal chemistry, , Sep-30, Volume: 37, Issue:20, 1994
1,8-disubstituted xanthine derivatives: synthesis of potent A2B-selective adenosine receptor antagonists.Journal of medicinal chemistry, , Mar-28, Volume: 45, Issue:7, 2002
Structure-activity relationships of 1,3-dialkylxanthine derivatives at rat A3 adenosine receptors.Journal of medicinal chemistry, , Sep-30, Volume: 37, Issue:20, 1994
Novel diamino derivatives of [1,2,4]triazolo[1,5-a][1,3,5]triazine as potent and selective adenosine A2a receptor antagonists.Journal of medicinal chemistry, , Mar-24, Volume: 48, Issue:6, 2005
Piperazine derivatives of [1,2,4]triazolo[1,5-a][1,3,5]triazine as potent and selective adenosine A2a receptor antagonists.Journal of medicinal chemistry, , Aug-12, Volume: 47, Issue:17, 2004
Adenosine A1 antagonists. 3. Structure-activity relationships on amelioration against scopolamine- or N6-((R)-phenylisopropyl)adenosine-induced cognitive disturbance.Journal of medicinal chemistry, , Aug-20, Volume: 36, Issue:17, 1993
Photoisomerization of a potent and selective adenosine A2 antagonist, (E)-1,3-Dipropyl-8-(3,4-dimethoxystyryl)-7-methylxanthine.Journal of medicinal chemistry, , Nov-12, Volume: 36, Issue:23, 1993
(E)-1,3-dialkyl-7-methyl-8-(3,4,5-trimethoxystyryl)xanthines: potent and selective adenosine A2 antagonists.Journal of medicinal chemistry, , Jun-12, Volume: 35, Issue:12, 1992
Chiral resolution and stereospecificity of 6-phenyl-4-phenylethynyl- 1,4-dihydropyridines as selective A(3) adenosine receptor antagonists.Journal of medicinal chemistry, , Aug-12, Volume: 42, Issue:16, 1999
Interaction of 1,4-dihydropyridine and pyridine derivatives with adenosine receptors: selectivity for A3 receptors.Journal of medicinal chemistry, , Jul-19, Volume: 39, Issue:15, 1996
1-alkyl-8-(piperazine-1-sulfonyl)phenylxanthines: development and characterization of adenosine A2B receptor antagonists and a new radioligand with subnanomolar affinity and subtype specificity.Journal of medicinal chemistry, , Jul-09, Volume: 52, Issue:13, 2009
1,8-disubstituted xanthine derivatives: synthesis of potent A2B-selective adenosine receptor antagonists.Journal of medicinal chemistry, , Mar-28, Volume: 45, Issue:7, 2002
Structure-activity relationships at human and rat A2B adenosine receptors of xanthine derivatives substituted at the 1-, 3-, 7-, and 8-positions.Journal of medicinal chemistry, , May-23, Volume: 45, Issue:11, 2002
Chiral resolution and stereospecificity of 6-phenyl-4-phenylethynyl- 1,4-dihydropyridines as selective A(3) adenosine receptor antagonists.Journal of medicinal chemistry, , Aug-12, Volume: 42, Issue:16, 1999
Interaction of 1,4-dihydropyridine and pyridine derivatives with adenosine receptors: selectivity for A3 receptors.Journal of medicinal chemistry, , Jul-19, Volume: 39, Issue:15, 1996
Adenosine A2A receptor as a drug discovery target.Journal of medicinal chemistry, , May-08, Volume: 57, Issue:9, 2014
Nucleosides and nucleotides. 112. 2-(1-Hexyn-1-yl)adenosine-5'-uronamides: a new entry of selective A2 adenosine receptor agonists with potent antihypertensive activity.Journal of medicinal chemistry, , Jul-24, Volume: 35, Issue:15, 1992
Adenosine receptors: pharmacology, structure-activity relationships, and therapeutic potential.Journal of medicinal chemistry, , Feb-07, Volume: 35, Issue:3, 1992
Highly selective adenosine A2 receptor agonists in a series of N-alkylated 2-aminoadenosines.Journal of medicinal chemistry, , Volume: 34, Issue:8, 1991
C2,N6-disubstituted adenosines: synthesis and structure-activity relationships.Journal of medicinal chemistry, , Volume: 32, Issue:8, 1989
N6-(arylalkyl)adenosines. Identification of N6-(9-fluorenylmethyl)adenosine as a highly potent agonist for the adenosine A2 receptor.Journal of medicinal chemistry, , Volume: 31, Issue:1, 1988
N6-[2-(3,5-dimethoxyphenyl)-2-(2-methylphenyl)ethyl]adenosine and its uronamide derivatives. Novel adenosine agonists with both high affinity and high selectivity for the adenosine A2 receptor.Journal of medicinal chemistry, , Volume: 31, Issue:7, 1988
N-cycloalkyl derivatives of adenosine and 1-deazaadenosine as agonists and partial agonists of the A(1) adenosine receptor.Journal of medicinal chemistry, , Jan-27, Volume: 43, Issue:2, 2000
Adenosine receptors: pharmacology, structure-activity relationships, and therapeutic potential.Journal of medicinal chemistry, , Feb-07, Volume: 35, Issue:3, 1992
Highly selective adenosine A2 receptor agonists in a series of N-alkylated 2-aminoadenosines.Journal of medicinal chemistry, , Volume: 34, Issue:8, 1991
4-Amino[1,2,4]triazolo[4,3-a]quinoxalines. A novel class of potent adenosine receptor antagonists and potential rapid-onset antidepressants.Journal of medicinal chemistry, , Volume: 33, Issue:8, 1990
C2,N6-disubstituted adenosines: synthesis and structure-activity relationships.Journal of medicinal chemistry, , Volume: 32, Issue:8, 1989
N6-phenyladenosines: pronounced effect of phenyl substituents on affinity for A2 adenosine receptors.Journal of medicinal chemistry, , Volume: 30, Issue:5, 1987
N6-cycloalkyladenosines. Potent, A1-selective adenosine agonists.Journal of medicinal chemistry, , Volume: 28, Issue:10, 1985
C4-substituted 1-beta-D-ribofuranosylpyrazolo[3,4-d]pyrimidines as adenosine agonist analogues.Journal of medicinal chemistry, , Volume: 26, Issue:11, 1983
Adenosine receptors: targets for future drugs.Journal of medicinal chemistry, , Volume: 25, Issue:3, 1982
Chiral resolution and stereospecificity of 6-phenyl-4-phenylethynyl- 1,4-dihydropyridines as selective A(3) adenosine receptor antagonists.Journal of medicinal chemistry, , Aug-12, Volume: 42, Issue:16, 1999
Structure-activity relationships of 4-(phenylethynyl)-6-phenyl-1,4-dihydropyridines as highly selective A3 adenosine receptor antagonists.Journal of medicinal chemistry, , Aug-01, Volume: 40, Issue:16, 1997
6-phenyl-1,4-dihydropyridine derivatives as potent and selective A3 adenosine receptor antagonists.Journal of medicinal chemistry, , Nov-08, Volume: 39, Issue:23, 1996
Interaction of 1,4-dihydropyridine and pyridine derivatives with adenosine receptors: selectivity for A3 receptors.Journal of medicinal chemistry, , Jul-19, Volume: 39, Issue:15, 1996
Structure-activity relationships and molecular modeling of 3, 5-diacyl-2,4-dialkylpyridine derivatives as selective A3 adenosine receptor antagonists.Journal of medicinal chemistry, , Aug-13, Volume: 41, Issue:17, 1998
2-Substitution of N6-benzyladenosine-5'-uronamides enhances selectivity for A3 adenosine receptors.Journal of medicinal chemistry, , Oct-14, Volume: 37, Issue:21, 1994
Structure-activity relationships of N6-benzyladenosine-5'-uronamides as A3-selective adenosine agonists.Journal of medicinal chemistry, , Mar-04, Volume: 37, Issue:5, 1994
Dual targeting of adenosine A(2A) receptors and monoamine oxidase B by 4H-3,1-benzothiazin-4-ones.Journal of medicinal chemistry, , Jun-13, Volume: 56, Issue:11, 2013
Potent, selective, and orally active adenosine A2A receptor antagonists: arylpiperazine derivatives of pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidines.Bioorganic & medicinal chemistry letters, , Mar-01, Volume: 17, Issue:5, 2007
Medicinal chemistry of A₃ adenosine receptor modulators: pharmacological activities and therapeutic implications.Journal of medicinal chemistry, , Jun-28, Volume: 55, Issue:12, 2012
Thiazole and thiadiazole analogues as a novel class of adenosine receptor antagonists.Journal of medicinal chemistry, , Mar-01, Volume: 44, Issue:5, 2001
Medicinal chemistry of A₃ adenosine receptor modulators: pharmacological activities and therapeutic implications.Journal of medicinal chemistry, , Jun-28, Volume: 55, Issue:12, 2012
Adenosine receptors: pharmacology, structure-activity relationships, and therapeutic potential.Journal of medicinal chemistry, , Feb-07, Volume: 35, Issue:3, 1992
C2,N6-disubstituted adenosines: synthesis and structure-activity relationships.Journal of medicinal chemistry, , Volume: 32, Issue:8, 1989
N6-(arylalkyl)adenosines. Identification of N6-(9-fluorenylmethyl)adenosine as a highly potent agonist for the adenosine A2 receptor.Journal of medicinal chemistry, , Volume: 31, Issue:1, 1988
N6-[2-(3,5-dimethoxyphenyl)-2-(2-methylphenyl)ethyl]adenosine and its uronamide derivatives. Novel adenosine agonists with both high affinity and high selectivity for the adenosine A2 receptor.Journal of medicinal chemistry, , Volume: 31, Issue:7, 1988
Nucleosides and nucleotides. 112. 2-(1-Hexyn-1-yl)adenosine-5'-uronamides: a new entry of selective A2 adenosine receptor agonists with potent antihypertensive activity.Journal of medicinal chemistry, , Jul-24, Volume: 35, Issue:15, 1992
Nucleosides and nucleotides. 107. 2-(cycloalkylalkynyl)adenosines: adenosine A2 receptor agonists with potent antihypertensive effects.Journal of medicinal chemistry, , Jun-12, Volume: 35, Issue:12, 1992
Adenosine receptors: pharmacology, structure-activity relationships, and therapeutic potential.Journal of medicinal chemistry, , Feb-07, Volume: 35, Issue:3, 1992
C2,N6-disubstituted adenosines: synthesis and structure-activity relationships.Journal of medicinal chemistry, , Volume: 32, Issue:8, 1989
N6-[2-(3,5-dimethoxyphenyl)-2-(2-methylphenyl)ethyl]adenosine and its uronamide derivatives. Novel adenosine agonists with both high affinity and high selectivity for the adenosine A2 receptor.Journal of medicinal chemistry, , Volume: 31, Issue:7, 1988
Design and in Vivo Characterization of AJournal of medicinal chemistry, , 02-14, Volume: 62, Issue:3, 2019
Optimization of adenosine 5'-carboxamide derivatives as adenosine receptor agonists using structure-based ligand design and fragment screening.Journal of medicinal chemistry, , May-10, Volume: 55, Issue:9, 2012
Structure-activity relationships of N6-benzyladenosine-5'-uronamides as A3-selective adenosine agonists.Journal of medicinal chemistry, , Mar-04, Volume: 37, Issue:5, 1994
N6-substituted N-alkyladenosine-5'-uronamides: bifunctional ligands having recognition groups for A1 and A2 adenosine receptors.Journal of medicinal chemistry, , Volume: 29, Issue:9, 1986
Adenosine receptors: targets for future drugs.Journal of medicinal chemistry, , Volume: 25, Issue:3, 1982
[no title available]European journal of medicinal chemistry, , Jan-15, Volume: 186, 2020
Medicinal chemistry of A₃ adenosine receptor modulators: pharmacological activities and therapeutic implications.Journal of medicinal chemistry, , Jun-28, Volume: 55, Issue:12, 2012
Imidazo[2,1-i]purin-5-ones and related tricyclic water-soluble purine derivatives: potent A(2A)- and A(3)-adenosine receptor antagonists.Journal of medicinal chemistry, , Aug-01, Volume: 45, Issue:16, 2002